Stockwinners Market Radar for December 08, 2022 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:50 EST Nerdy to cut 17% of its workforce - In a regulatory 8-K filing, Nerdy states: "On December 8, 2022, Nerdy announced the completion of workforce reductions of approximately 17 % of the Company's total workforce. The reductions primarily affected variable hourly roles and included a limited number of corporate fixed personnel roles. The new products and go-to-market strategies in both the Company's Consumer and Institutional business categories, which focus on recurring revenue relationships with higher value customers, allow for a simplified sales model and generate operating efficiencies, including in the headcount needed to operate certain areas of the business. The Company does not expect any negative impact on its ability to meet the evolving needs of its customers, its ability to grow revenue, or its capacity for innovation as a result of these actions. These decisions, in combination with other cost-reduction measures, are intended to reduce operating expenses in support of the Company's stated goal to achieve adjusted-EBITDA profitability by the end of 2023, as previously communicated. The Company currently estimates that it will incur one-time charges in the fourth quarter of 2022 of approximately $1 million to $2 million in connection with the workforce reductions, primarily for severance payments and related employee benefit costs. The Company expects that the implementation of the headcount reductions, including cash payments, will be substantially complete by the end of the fourth quarter of 2022."

19:18 EST Myriad Genetics presents results validating RiskScore in breast cancer detection - The company states: "Myriad Genetics presented results from a longitudinal study validating RiskScore as a well-calibrated and more accurate predictor of breast cancer risk than a standard-of-care risk assessment alone. The data was shared in a spotlight discussion at the 2022 San Antonio Breast Cancer Symposium. Working with industry-leading researchers, Myriad Genetics studied outcomes from more than 130,000 women who received RiskScore results. By analyzing data on whether women developed breast cancer after their initial test result, the study demonstrated that RiskScore was more accurate at stratifying women at high- or low-risk of developing breast cancer than a standard of care risk assessment method. Based on these findings, clinical use of RiskScore may lead to improved breast cancer prevention and screening strategies."

18:46 EST Veeva director sells $1.64M in common stock - In a regulatory filing, Veeva disclosed that its director Timothy Cabral sold 10K share of common stock on December 6 in a total transaction size of $1.64M.

18:44 EST Douglas Emmett announces $300M share repurchase authorization - Douglas Emmett announced that its Board of Directors has authorized the repurchase of up to $300M of its outstanding common shares under a newly established share repurchase program.

17:35 EST Chewy says now expects FY22 capex to come in slightly below 2.5% of sales - Says ended the third quarter with 20.5M active customers. Says gross customer additions accelerated 6% sequentially. Says customer retention rates remain stable. Says bullish on pet insurance space. Says operating space remains dynamic. Comments and guidance taken from Q3 earnings conference call.

17:33 EST Lockheed Martin awarded $328.53M Navy contract modification - Lockheed Martin was awarded a $328.53M cost-plus-incentive-fee and cost-plus-fixed-fee contract for the U.S. and United Kingdom to provide Strategic Weapon System Trident Fleet support, Trident II Shipboard Integration Increment 8, and navigation subsystem development efforts. This contract award also benefits a foreign military sale to the United Kingdom. Work is expected to be completed by September 30, 2026. FY23 operation and maintenance funds in the amount of $13.18M; and FY23 shipbuilding and conversion funds in the amount of $17.39M will be obligated at time of award. FY23 operation and maintenance funds in the amount of $13.18M will expire at the end of the current fiscal year. This contract is being awarded as a sole-source pursuant to 10 U.S. Code 3204 and. Strategic Systems Programs is the contracting activity.

17:22 EST Fiesta Restaurant names Dirk Montgomery as interim CEO - Fiesta Restaurant "announced that Richard "Rich" Stockinger has stepped down from his role as the company's CEO and President to pursue other interests, effective immediately. Dirk Montgomery, Fiesta's CFO since 2019, will serve as interim CEO while the company searches for a permanent chief executive."

17:01 EST Infobird receives delinquency notification letter from Nasdaq - Infobird announced that it received a delinquency notification letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC on December 6, 2022 indicating that the company is not currently in compliance with the minimum bid price requirement set forth in Nasdaq's Listing Rules for continued listing on the Nasdaq Capital Market, as the closing bid price for the company's ordinary shares listed on the Nasdaq Capital Market was below $1.00 per share for 30 consecutive business days. Nasdaq Listing Rule 5550(a)(2) requires listed securities to maintain a minimum bid price of $1.00 per share, and Nasdaq Listing Rule 5810(c)(3)(A) provides that a failure to meet the minimum bid price requirement exists if the deficiency continues for a period of 30 consecutive business days. The Notice provides that the company has a period of 180 calendar days from the date of the Notice, or until June 5, 2023, to regain compliance with the minimum bid price requirement.

16:52 EST Ambac Financial says 'not engaged in an acquisition process' - Ambac Financial Group released the following statement: "Ambac has become aware of a media report indicating it is in discussions to acquire a financial guarantee company. This report is inaccurate. Ambac is not engaged in an acquisition process with any financial guarantee business. Management is regularly evaluating the market for opportunities to create value for shareholders and will update investors as appropriate."

16:50 EST CNO Financial appoints Chief Operation and Chief Information Officers - CNO Financial is elevating two key senior leaders to the company's Executive Leadership Group: Jean Linnenbringer as COO and Mike Mead as Chief Information Officer. Both appointments are effective January 1, 2023. Linnenbringer has more than 30 years of operations management experience in the insurance and financial services industries. She joined CNO in 2015 and since August 2017 has served as the company's Senior VP of enterprise operations. Mead has more than 25 years of experience in general management and technology leadership within the insurance industry. He joined CNO in 2018 as Senior VP and Chief Information Officer. Linnenbringer and Mead succeed Bruce Baude, Chief Operations and Technology Officer, who is leaving his current role as of December 31, 2022.

16:48 EST Waste Management raises quarterly dividend to 70c from 65c per share - WM "announced that its Board of Directors has approved a 7.7% increase in the planned quarterly dividend rate for 2023, from $0.65 to $0.70 per share. The annual dividend rate increase from $2.60 to $2.80 per share marks the twentieth consecutive year of dividend rate increases."

16:42 EST BRT Apartments CEO buys $319K in common stock - In a regulatory filing, BRT Apartments disclosed that its CEO Jeffrey Gould bought 15.9K shares of common stock on December 6th in a total transaction size of $319.1K.

16:35 EST Exelixis trading resumes

16:32 EST Monro announces strategic initiatives, will waive battery installation charges - Monro recently implemented a series of initiatives designed to help customers prepare for winter driving. These efforts are part of a forward-looking strategic plan to position the company as a strong competitor in every market across the country. Monro now offers free battery checks and, in a departure from the industry standard, is waiving the installation charge for batteries. This applies to batteries either under the hood or in the trunk. The company has also rolled out several enhanced offerings in time for the holiday season, including: Extended store hours across all brands; A walk-in oil service option to provide hassle-free service, in addition to its online appointment system; Good-Better-Best oil service package updates to give customers competitively priced options that meet their budgets; A call-back program to personally remind customers when their next oil service is due; The roll-out of a new integration with CARFAX to provide customers with their vehicle service history and manufacturer recalls while in-store with service recommendations to enable more informed decision-making.

16:31 EST Territorial Bancorp declares 10c per share special cash dividend - Territorial Bancorp announced that its board of directors has declared a special cash dividend of 10c per share payable on December 29 to shareholders of record as of December 19.

16:29 EST Exelixis to resume trading at 4:35 pm ET - Exelixis shares are scheduled to resume trading at 4:35 pm ET, with quotation set to resume at 4:30 pm ET, according to Nasdaq. The stock was halted, pending news, ahead of the company announcing that the phase 3 CONTACT-01 study evaluating cabozantinib in combination with atezolizumab did not meet its primary endpoint of overall survival at the final analysis.

16:27 EST Braemar Hotels & Resorts increases common dividend - Braemar Hotels & Resorts increased its quarterly cash dividend from 1c per share to 5c per share beginning with the company's common stock dividend for Q4 ending December 31, 2022. The dividend is payable on January 17, 2023, to stockholders of record as of December 30, 2022. The company expects to pay a quarterly cash dividend of 5c per share for 2023, or 20c per share on an annualized basis.

16:26 EST Lululemon falls 9% to $340.75 after Q3 results and guidance

16:22 EST Trinity Industries announces new $250M share buyback program - The Company announced the retirement of its current share repurchase authorization and a new $250M program authorized by its Board of Directors, effective December 9, 2022, with no expiration.

16:21 EST FlexShopper acquires certain assets of Revolution Financial - FlexShopper announced the purchase of certain assets of Revolution Financial and six affiliated entities. This purchase provides FlexShopper with 22 physical store locations, 78 virtual locations located within Liberty Tax stores and related digital assets in which FlexShopper will make available consumer financing solutions. This purchase is also the initial foray into a nationwide expansion of direct to consumer brick- and- mortar locations. "This acquisition provides a head start on the operational capabilities to begin our nationwide rollout as part of the previously announced Liberty Tax partnership." said Richard House, CEO of FlexShopper.

16:21 EST La-Z-Boy portfolio brands president Otis Sawyer to retire, Tj Linz to succeed - La-Z-Boy announced the planned retirement of Otis Sawyer, president, La-Z-Boy Portfolio Brands. Tj Linz, president, La-Z-Boy Retail, will assume Sawyer's responsibilities at the end of April 2023, the start of the company's fiscal 2024 year. Sawyer will remain with the company through June 2023 to ensure a transition.

16:20 EST Brookdale Senior Living reports November 2022 occupancy of 77% - Brookdale Senior Living reported weighted-average consolidated occupancy for November 2022 of 77%. Occupancy at month end was 78.1%. November's weighted average occupancy increased 350 basis points year-over-year. Q4-to-date weighted average occupancy increased 70 basis points compared to the full Q3. Achieved thirteen consecutive months of year-over-year weighted average occupancy growth. Weighted average occupancy grew 760 basis points since the start of the recovery in March 2021.

16:20 EST Axis Capital announces new $100M share buyback, raises quarterly dividend by 1c - AXIS Capital Holdings Limited announced that its Board of Directors has authorized the repurchase of up to $100M of the company's common shares, which may be effected from time to time in open market or privately negotiated transactions through December 31, 2023. The company intends to repurchase common shares opportunistically, when the timing and amount of the repurchases depending on a variety of factors, including market conditions and corporate and regulatory conditions. The company's Board of Directors has also declared a quarterly dividend of 44c per common share payable on January 18, 2023 to shareholders of record at the close of business on December 30, 2022.

16:19 EST Guardant Health announces collaboration with AstraZeneca - Guardant Health, Inc. (GH) announced it has entered into a collaboration with AstraZeneca (AZN) to pursue the development, regulatory approval and commercialization of the Guardant360 CDx blood test as a companion diagnostic to identify patients with ESR1-mutated metastatic breast cancer. The initiative is part of a larger strategic collaboration investigating the use of liquid biopsy as a tool to inform early therapy intervention. The collaboration is one of the first to explore the potential of a comprehensive genomic profiling ctDNA (circulating tumor DNA) assay to identify mutation-driven resistance to a prior line of therapy in metastatic breast cancer. The Guardant360 CDx liquid biopsy test is being used to identify patients with detectable ESR1 mutations in the SERENA-6 phase III clinical trial, which is evaluating camizestrant, a next-generation oral selective estrogen receptor degrader (ngSERD) being developed by AstraZeneca, in combination with CDK4/6 inhibitors versus aromatase inhibitors in combination with CDK4/6 inhibitors in patients with HR-positive, HER2-negative metastatic breast cancer. "We're pleased to collaborate with AstraZeneca on this important study for breast cancer patients," said Helmy Eltoukhy, Guardant Health chairman and co-CEO. "We look forward to exploring the potential benefit of early comprehensive genomic profiling using a simple blood draw, which can provide faster results than a tissue biopsy and enable clinicians to consider earlier intervention with the goal of achieving improved patient outcomes."

16:17 EST Paysafe announces reverse stock split - Paysafe Limited announced that its Board of Directors has approved a consolidation and redesignation of the issued and unissued common shares of par value $0.001, and the unissued undesignated shares, of par value $0.001, at a ratio of 1-for-12, such that after giving effect to the reverse stock split, the authorized share capital of the Company shall be comprised of $22,000,000 divided into 1,600,000,000 common shares of par value $0.012 each and 233,333,333.3 undesignated shares of par value $0.012 each. The reverse stock split will be effective at 4:01 p.m. (ET) on December 12, 2022, and the Common Shares will begin trading on a split-adjusted basis when the New York Stock Exchange opens for trading on Tuesday, December 13, 2022. The Common Shares will continue to trade on the NYSE under the trading symbol "PSFE", but will trade under the following new CUSIP number starting December 13, 2022: G6964L 206. The reverse stock split was approved by Paysafe's shareholders at the special general meeting of shareholders held on December 8, 2022 with over 95% approval for all proposals.

16:17 EST Terex appoints Stacey Babson Kaplan Chief Sustainability and Compliance Officer - Terex has promoted Stacey Babson Kaplan to Senior VP, Chief Sustainability and Compliance Officer, effective immediately. Babson Kaplan joined Terex in 2002 as Corporate Counsel, Human Resources Compliance. In 2005, she was appointed Vice President, Deputy General Counsel, Employment & Global Diversity. She was named Vice President, Chief Ethics & Compliance Officer in 2008.

16:16 EST Bath & Body Works up 9% after Third Point reveals stake, voices concerns - Shares of Bath & Body Works are up $3.84, or 9%, to $46.00 in after-hours trading following Dan Loeb's Third Point reporting it has a 6.02% stake.

16:15 EST Inotiv announces new site openings, capacity expansion - Inotiv announced the opening of the second phase of its lab facility in Rockville, Maryland, the scheduled opening date of January 2023 for its pathology campus and training center in Kalamazoo, Michigan, and the opening and occupancy of the site expansion at its facility in Boulder, Colorado. These openings and expansions reflect the company's ongoing initiatives to broaden its portfolio of pre-clinical and clinical service offerings. Finally, the company has completed the expansion of its Boulder, Colorado, facility, resulting in approximately 30% additional capacity to support its discovery pharmacology and histopathology offerings.

16:15 EST Quest Diagnostics partners with Northern Light Health in Maine - Quest Diagnostics and Northern Light Health, a large integrated healthcare system in Maine, announced a strategic laboratory collaboration. Quest will acquire select assets of Northern Light Health's outreach laboratory services business, named Northern Light Laboratory, in an all-cash transaction. Quest will also provide professional laboratory management services for nine of Northern Light Health's hospital laboratories, along with its cancer center laboratory at Northern Light Cancer Care in Brewer, Maine. The parties expect to complete the transaction in 1Q23. Financial details of the transaction were not disclosed. Quest's laboratory in Marlborough, Mass. will provide non-urgent advanced and routine clinical testing for physicians and patients now serviced by Northern Light Laboratory.

16:14 EST RH CEO to exercise expiring options - RH "announced that Chairman & Chief Executive Officer Gary Friedman intends to sell approximately 0.7 million shares of common stock related to 1.0 million options that are set to expire in connection with the ten-year anniversary of the grant date of July 2013. Mr. Friedman plans to use the sale proceeds to fund the option exercise and satisfy the resulting tax obligations. Following the option exercise and sale, Mr. Friedman will retain beneficial ownership of approximately 5.0 million shares, representing approximately 19% of RH's common stock outstanding."

16:13 EST Third Point reports 6.02% stake in Bath & Body Works - Dan Loeb's Third Point reported a 6.02% stake in Bath & Body Works, stating the firm has "significant experience in advising public companies on matters of corporate governance, board composition and capital allocation" and believes "that certain decisions by the Issuer's Board of Directors raise questions about the adequacy of current governance practices." Third Point believes that the company, through the compensation committee of the Board, "has made errors in structuring its executive compensation such that excessive awards have been made that are untethered to important performance metrics" and has "significant concerns about financial discipline, investor communication, and Board composition, including the ability of current Board members to make long-term value-maximizing decisions through responsible and thoughtful capital allocation." In the event no satisfactory resolution is reached, the firm reserves "the right to seek changes in Board composition and/or take other measures at or before the Company's next annual meeting," the filing stated.

16:12 EST Alliance Resource Partners names Cary P. Marshall as new CFO - Alliance Resource Partners announced that the Board of Directors of its general partner, Alliance Resource Management GP, LLC, has appointed Cary P. Marshall as Senior Vice President and CFO effective April 1, 2023. The appointment follows the Partnership's previously announced retirement and succession plan for Brian L. Cantrell, current Chief Financial Officer. Mr. Cantrell will remain with Alliance through March 31, 2023, to facilitate an orderly transition.

16:12 EST Vail Resorts still sees FY23 net income $321M-$396M - Still sees FY23 resort reported EBITDA guidance of $893M-$947M. CEO Lynch said, "It is important to note that there continues to be uncertainty around the economic outlook and the impact that may have on travel and consumer behavior as we head into our primary operating season. Our guidance includes an estimated $4M of acquisition and integration related expenses in fiscal year 2023 associated with the acquisitions of the Seven Springs Resorts and our majority ownership in Andermatt-Sedrun. Foreign currency exchange rates have experienced recent volatility".

16:11 EST Sierra Lake Acquisition announces liquidation - Sierra Lake Acquisition Corp. announced that due to its inability to consummate an initial business combination within the time period required by its Amended and Restated Certificate of Incorporation the company intends to dissolve and liquidate in accordance with the provisions of its Amended Charter, effective as of the close of business on December 8, 2022, and will redeem all of the outstanding shares of Class A common stock that were included in the units issued in its initial public offering, at a per-share redemption price of approximately $10.12. As of the close of business on December 16, 2022, the Public Shares will be deemed cancelled and will represent only the right to receive the redemption amount.

16:09 EST Veritiv CFO Stephen Smith to retire, Eric Guerin to succeed - Veritiv announced that Stephen "Steve" Smith, the company's Senior Vice President and CFO, has informed the Veritiv Board of Directors that he intends to retire from the company in September 2023. Eric Guerin, a seasoned finance leader, will succeed Smith as Senior Vice President and CFO on March 1, 2023. To ensure a smooth transition, Guerin will join Veritiv on January 1, 2023, as Senior Vice President - Finance, and will officially assume the role of Senior Vice President and CFO on March 1, 2023. Smith will remain with the company in an advisory capacity until his retirement on September 30, 2023. Guerin most recently served as Executive Vice President and CFO of CDK Global, formerly a publicly traded provider of retail technology and software-as-a-service solutions.

16:07 EST Lululemon reports Q3 SSS up 22% or 25% on constant FX basis

16:04 EST Autolus Therapeutics announces FELIX trial meets primary endpoint - Autolus Therapeutics announced that the Phase 2 pivotal FELIX clinical trial of obecabtagene autoleucel in relapsed/refractory adult Acute Lymphoblastic Leukemia, or ALL, has met its primary endpoint, based on a pre-planned interim analysis of 50 patients with morphological disease, as verified by an independent data monitoring committee, or IDMC. The primary endpoint for the FELIX Phase 2 trial is the Overall Remission Rate, or ORR, defined as the proportion of patients achieving Complete Remission, or CR, and Complete Remission with Incomplete Blood Count Recovery, or CRi, as assessed by an independent response review committee, or IRRC. Based on 50 patients evaluated for efficacy, the ORR for obe-cel was 70%. Obe-cel showed comparable expansion and initial persistence to the data observed in the prior ALLCAR19 study. The safety analysis was based on 92 patients treated with obe-cel and evaluable for safety. The company observed that 3% of patients experienced Grade 3 or higher CRS, whilst 8% experienced Grade 3 or higher ICANS, and 23% of patients experienced any grade ICANS. The trial has completed screening patients for entry into the morphological cohort as the pre-specified goal of approximately 90 patients enrolled has been reached, and Autolus plans to present the results from the FELIX trial at a medical conference in mid-2023, with longer follow up planned to be reported at the end of 2023.

16:02 EST Exelixis trading halted, news pending

16:00 EST Venus Acquisition Corp trading resumes

14:52 EST Activision Blizzard CEO confident Microsoft deal will close - Activision Blizzard (ATVI) CEO Bobby Kotick sent the following letter to all employees: "I wanted to provide a brief update on our pending merger with Microsoft (MSFT). This week the U.S. Federal Trade Commission announced its decision to challenge the deal. This means they will file a lawsuit to block the merger, and arguments will be heard by a judge. This sounds alarming, so I want to reinforce my confidence that this deal will close. The allegation that this deal is anti-competitive doesn't align with the facts, and we believe we'll win this challenge. Thanks to the hard work by all of you every day, we're on a strong path, bringing epic joy to players around the world with what I believe are the greatest games in the industry. At the same time, the competitive landscape is shifting, and, simply put, a combined Microsoft-ABK will be good for players, good for employees, good for competition and good for the industry. Our players want choice, and this gives them exactly that. You can read more about the specifics on those points in this update we recently shared with you. We believe these arguments will win despite a regulatory environment focused on ideology and misconceptions about the tech industry. Thank you for your dedication and creativity."

14:29 EST Phanes Therapeutics announces clinical supply agreement with BeiGene - Phanes Therapeutics announced a clinical supply agreement with BeiGene to evaluate the safety and efficacy of Phanes' PT199, a differentiated anti-CD73 monoclonal antibody in combination with BeiGene's tislelizumab, an anti-PD-1 monoclonal antibody in the Phase I clinical study for the treatment of multiple advanced solid tumors. "We are excited about the opportunity to evaluate PT199 in combination with tislelizumab for the treatment of solid tumors. PT199 is an anti-CD73 monoclonal antibody with a differentiated mechanism of action to counter the immunosuppressive tumor microenvironment in cancer patients. The combination of PT199 with tislelizumab provides a new opportunity to assess the strategy to enhance antitumor immune response in patients with advanced or metastatic cancer refractory to previous treatments," said Dr. Ming Wang, Founder and CEO of Phanes.

13:56 EST Activision falls 2% to $74.05 after Bloomberg report of FTC suit

13:41 EST Novonix trading halted, volatility trading pause

13:11 EST Avery Dennison experiencing 'challenging' finish to the year, says CEO - Avery Dennison Chairman and CEO Mitchell Butler said in a fireside chat hosted by Bank of America that the company is seeing a "challenging" finish to the year, but expects to end the year with double digit organic growth and double digit EPS growth ex-currency. Quarter to date, Butler said revenue has been off the company's previous forecast by about $100M, so the company is activating its recession scenario plan that both take near-term cost reduction actions and mitigate the lower volumes.

12:31 EST MoneyLion sees medium-term adjusted revenue CAGR of 35%-50% - For the medium-term, sees adjusted gross profit margin 55%-65%, with an adjusted revenue CAGR of 35%-50%, and 20%-30% adjusted EBITDA positive margins. Comments taken from investor presentation slides.

12:16 EST BML takes 15% stake in Metracrine, plans to vote against merger - Braden Leonard's BML Investment Partners disclosed a 15.2% stake in Metracrine (MTCR), which represents over 6.4M shares. The filing with the SEC allows for activism. BML said it plans to vote against the company's proposed merger with Equillium (EQ) "unless the collar is adjusted to reflect the current Equillium share price."

12:00 EST Argan falls -10.8% - Argan is down -10.8%, or -$4.04 to $33.21.

12:00 EST Membership Collective rises 13.6% - Membership Collective is up 13.6%, or 48c to $4.00.

12:00 EST Ciena rises 19.9% - Ciena is up 19.9%, or $8.59 to $51.83.

11:46 EST Commercial Metals selects West Virginia as site of fourth micro mill - Commercial Metals Company announced that it has selected Berkeley County, West Virginia, as the site of its fourth micro mill. The project, budgeted to cost approximately $450M net of incentives, is expected to have an annual capacity of 500,000 tons and employ approximately 230 people on a full-time basis. MM4 will be capable of producing various sizes of both straight length and spooled rebar. Based on anticipated timelines for permitting and construction, the new plant is scheduled to begin operations in late calendar 2025.

11:05 EST Spearline acquires Callstats from 8x8, terms not disclosed - Spearline has acquired Callstats analytics, diagnostics and optimization technology for WebRTC from 8x8, for an undisclosed sum. 8x8 is headquartered in California, USA. This acquisition will enable Spearline to utilise Callstats' proprietary technology to provide the best in class solution for testing and monitoring critical business telecommunication services for its global client base. Spearline's solutions provide businesses with the tools needed to improve and accelerate their customer experience. This deal will further expand Spearline's existing product suite, and follows the company's acquisition of the Israeli-based communications solutions provider testRTC in November of last year.

10:42 EST Pfizer, BioNTech announce EUA for bivalent COVID vaccine for children under 5 - Pfizer (PFE) and BioNTech SE (BNTX) announced the U.S. Food and Drug Administration granted Emergency Use Authorization, or EUA, of their Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine as the third 3-microgram dose in the three-dose primary series for children 6 months through 4 years of age. Children in this age group can receive a primary series consisting of two 3-microgram doses of the original Pfizer-BioNTech COVID-19 Vaccine followed by a third 3-microgram dose of the bivalent vaccine to complete the primary series. Vaccine doses can be delivered immediately upon receipt of a recommendation from the U.S. Centers for Disease Control and Prevention, the companies stated.

10:34 EST Nokia launches second EUR 300M phase of share buyback program - In line with the announcement on 3 February 2022, the Board of Directors of Nokia Corporation has decided to launch the second EUR 300M phase of the share buyback program that aims to return up to EUR 600M of cash to its shareholders in tranches over a period of two years. Repurchases are expected to resume in early January. The first phase of the share buyback program with a maximum aggregate purchase price of EUR 300M was initiated on 14 February 2022 and it was completed on 11 November 2022.

10:16 EST Locafy Ltd trading resumes

10:12 EST Cinedigm launches El Rey Network, Real Madrid TV on Amazon Freevee - Cinedigm launched two linear channels on Amazon Freevee - El Rey Network, which delivers a mix of incredible Latinx-inclusive content curated by director Robert Rodriguez and Realmadrid TV, offering matches and more featuring one of the world's most recognized sports team brands. This announcement comes on the heels of Cinedigm, in conjunction with The Nacelle Company, launching the 24/7 OTT pop-culture channel, NacellePop, exclusively on Freevee.

10:10 EST PHP Ventures Acquisition, Modulex enter business combination agreement - Modulex Modular Buildings and PHP Ventures Acquisition announced the signing of a definitive business combination agreement. After the closing of the transactions contemplated in the BCA, Modulex will become a publicly listed company and PHP will become a subsidiary of Modulex. Modulex expects to be listed on the Nasdaq Capital Market under the symbol "MDLX." The Combined Company would have an approximate post-transaction equity market capitalization of $723 million assuming a $10.00 per share price and no redemptions by PHP stockholders and completion of an additional $30 million of financing. Pursuant to the terms of the Business Combination Agreement, at closing of the Transactions, the following is expected to occur: a newly-organized, wholly-owned subsidiary of Modulex will merge into PHP resulting in PHP becoming a wholly-owned subsidiary of Modulex, Modulex will register as a publicly traded company and parent of PHP, Modulex's existing shares will be split to facilitate a fully diluted value per Modulex share of $10, and PHP's common stock and warrants to purchase PHP common stock will be exchanged on a one-for-one basis for Modulex Ordinary Shares and warrants to purchase Modulex Ordinary Shares, respectively. Prior to the closing of the BCA, but subject to the completion of the Merger, Modulex will effect a recapitalization of its outstanding equity securities so that the pre-Merger holders of Modulex Ordinary Shares, options and warrants to acquire Modulex Ordinary Shares will have shares valued at $10.00 per share and having a total value of $600 million, which does not include any shares issued as part of any pre-transaction rounds of financing in Modulex. This will result in the pre-Merger and pre-financing Modulex shareholders holding approximately 86.21% post transaction undiluted Modulex Ordinary Shares, assuming no redemptions by PHP shareholders, and other assumptions to be set forth in a registration statement to be filed by Modulex on Form F-4 with the U.S. Securities and Exchange Commission. All pre-Merger directors, officers and founding shareholders of Modulex Ordinary Shares will be subject to a lockup of 90% of their shares for a period ending three years from the closing of the merger. Additionally, minority shareholders of Modulex will be subject to a lockup of 90% of their shares for a period of two years from the closing date of the merger. The closing of this proposed Transactions is subject to agreement to these lockups by 90% of the minority shareholders and founding shareholders, respectively, which term may be amended or waived by PHP at their sole discretion. In addition to the $58 million held in PHP's trust accoun, proceeds to the Combined Company in the proposed business combination for PHP and Modulex would potentially include up to US$30 million in pre-transaction financing, a PIPE, or other alternatives. The final amount of any pre-transaction financing, or financing in connection with the proposed Business Combination, if any, to be raised is by mutual agreement and dependent on market conditions, and related terms, if any, have not been finalized. The Combined Company is expected to receive net proceeds after the US$30 million financing of approximately US$82.5 million assuming no redemptions and after transaction-related expenses of approximately US$5.6 million. Use of net proceeds, among other things, is expected to fund development for organic growth and expansion, including funding for five factories across South Korea, Vietnam, Brazil, Egypt and the U.S. and positions Modulex to roll out a further 15 factories across emerging markets, and for working capital. The Business Combination has been unanimously approved by the boards of directors of both PHP and Modulex, and is expected to close in the second quarter of 2023, subject to review and approval by the SEC of the Registration Statement to be filed with the SEC, regulatory and stockholder approvals and other customary closing conditions set forth in the BCA. The group may seek up to US$30 million in pre-transaction financing, a PIPE, or other financing alternatives prior to the closing of the Business Combination with a transaction structure yet to be determined. The closing of the Business Combination has no minimum closing condition.

10:05 EST Blue Bird partners with Highland Electric Fleets for 12 electric school buses - Blue Bird Corporation has teamed up with Highland Electric Fleets to make it simpler and more affordable for Hardin County Community Unit School District #1 in Illinois to upgrade to clean electric school buses. The school district ordered 12 Blue Bird Type C electric school buses through Highland. Highland's innovative fleet electrification-as-a-service offering allows districts and third-party fleet managers to avoid the upfront costs and complexity of electrification, accelerating the adoption of clean student transportation.

10:01 EST Korn Ferry falls -8.7% - Korn Ferry is down -8.7%, or -$4.67 to $49.27.

10:00 EST Chart Industries falls -10.3% - Chart Industries is down -10.3%, or -$13.95 to $121.02.

10:00 EST GMS Inc. rises 8.6% - GMS Inc. is up 8.6%, or $4.25 to $53.63.

09:47 EST Eve, FlyBIS enter LOI to develop eVTOL operations in Brazil, Latin America - Eve Air Mobility has signed a Letter of Intent with FlyBIS Aviation, an air mobility start-up based in Caxias do Sul, in the south of Brazil, to collaborate on the development of eVTOL operations in Brazil and South America. Based on the agreement, FlyBIS will also purchase up to 40 of Eve's eVTOL vehicles. After starting operations in Brazil's southern states, FlyBIS plans to expand operations to neighboring countries and contribute to the implementation and development of Eve's air mobility ecosystem. FlyBIS is backed by Brave Aviation whose current fleet includes Embraer Phenom 100 as well as other aircraft. FlyBIS' vehicles are included in Eve's order backlog of up to 2,770 eVTOLs.

09:47 EST Lincoln National falls -7.3% - Lincoln National is down -7.3%, or -$2.57 to $32.71.

09:47 EST GMS Inc. rises 8.5% - GMS Inc. is up 8.5%, or $4.21 to $53.59.

09:47 EST Ciena rises 17.9% - Ciena is up 17.9%, or $7.74 to $50.98.

09:34 EST American Express appoints Deborah Majoras to board of directors - American Express Company (AXP) announced that Deborah Platt Majoras has been elected to its Board of Directors, effective December 7, 2022. Majoras served as Chief Legal Officer and Corporate Secretary of Procter & Gamble (PG) for 12 years until her retirement earlier this year and was previously Chair of the Federal Trade Commission from 2004 until 2008.

09:30 EST Kaman to consolidate JPF program, optimize cost structure - Kaman announced actions to continue reshaping the company's portfolio, enhance operational efficiency, improve financial performance and position Kaman for long-term growth and sustainable value creation. As the JPF program winds down, the company will consolidate the production of fuzes at Kaman's Middletown, Connecticut facility, which has the potential capacity to deliver against future direct commercial sales. Given the completion of the Joint Air-to-Surface Standoff Missile program and evolving market trends, the Orlando facility is expected to fully cease operations by the end of 2024. The actions taken with respect to Orlando are expected to result in annualized run-rate cost savings of approximately $12M to $15M and total pre-tax restructuring charges of $8M to $10M. Kaman will continue improving its legacy structures programs, enhancing overall execution and focusing on winning new and more profitable programs, including growing the company's aftermarket portfolio. In all businesses, Kaman will maintain focus on continuous improvement, reducing variation and inefficiencies in the Company's value streams. Kaman is also in the process of streamlining and re-sizing the corporate organization to better reflect the current size of the company, while also executing SG&A reductions at the strategic business unit ("SBU") level driven by reducing layers, consolidating support functions, eliminating redundancies between corporate and SBU, among other efforts. These actions support Kaman's objective to de-lever its balance sheet, improve net working capital, expand gross margins and increase overall EBITDA and free cash flow generation. The company expects these combined efforts to result in greater alignment of its cost structure with future growth opportunities, enhancing Kaman's long-term competitive profile. As part of Kaman's portfolio reshaping efforts, the management team continues to evaluate the company's business lines and programs with the goal of best positioning Kaman to deliver long-term shareholder value creation. The company plans to provide an estimate of its annualized cost savings objective as well as an update on its ongoing portfolio shaping and cost reduction efforts early in the first quarter of 2023.

09:27 EST ONUART Foundation, UNAOC launches 'One Humanity ID' project - The ONUART Foundation and WISeKey International Holding announced the launch of the One Humanity ID, a Digital Identity platform developed by WISeKey. The collaboration delivers a new Digital Identity platform, based in WISeKey's platform "WISeID", that is linked with different initiatives derived of the strategic partnership between both entities. With this new project, the ONUART Foundation opens the possibility to all citizens of the world to show their support in favor of the "One Humanity World," a new global architecture oriented to put the individual at the center of the international system. We are moving towards a new era, the era of intelligence, and we must create a new global frame to allow all individuals to feel free and secure and explore their capacities. Human Rights should be the backbone of this new global world. Becoming a member of the "One Humanity ID" platform collectivity will enlarge the power of all of us and will make of our aspiration a reality.

09:23 EST Hovnanian reports Q4 EPS $7.24 vs. $7.41 last year - Reports Q4 revenue $886.8M vs. $814.3M last year. "We are pleased with the strong performance for our fourth quarter and fiscal year. We exceeded our full year guidance for adjusted pretax income and adjusted EBITDA. Our strong performance in fiscal 2022 was partially the result of deliveries which were contracted during a time when demand for new homes was much stronger than it is today," stated Ara Hovnanian, CEO. "The current level of demand for new homes is significantly lower and continues to be burdened by high levels of inflation, a sharp increase in mortgage rates and concerns about an economic recession. Given the strong margins in our large fourth quarter backlog and to minimize any potential disruption to those deliveries and margins, we were not aggressive with concessions on new contracts during the fourth quarter. Additionally, to eliminate the risk of further mortgage rate increases, consumers are seeking homes where they can close quickly. In response to that demand, we ended the year with 5.6 quick move in homes per community, compared to 3.2 at the end of the third quarter and our long-term average of 4.4 quick move in homes per community. Therefore, we felt it was prudent to postpone larger incentives until the increased level of quick move in homes we started during the third and fourth quarter were closer to being completed. Now that the fourth quarter is behind us and because of the progress we have made on constructing additional quick move in homes, we are now becoming more aggressive in our attempts to find the market price that will spur demand in each of our markets.During a period of declining housing demand, it is important that we focus on preserving liquidity. We ended our fiscal year with $457 million of liquidity, significantly above the $245 million high end of our target range. We remain committed to strengthening our balance sheet and intend to revisit our debt retirement initiatives once market conditions improve. Despite the near-term uncertainty in the housing market, we believe that the long-term fundamentals remain intact and as the economy and mortgage market reach stability, it should lead to a more robust housing market that returns sales pace per community to more normalized levels," concluded Mr. Hovnanian.

09:19 EST Live Current Media enters LOI to acquire GoFamer Oy in $250,000 transaction - Live Current Media announces that it has signed a non-binding letter of intent to acquire GoFamer Oy of Finland in an all stock transaction. Pursuant to the terms of the LOI, Live Current will purchase all of the outstanding share capital of GoFamer Oy in an all stock transaction valued at $250,000. As part of the transaction, Jere Virtanen, GoFamer's CEO and founder, will enter into an employment agreement with Live Current on mutually agreeable terms. The final transaction is subject to due diligence by both companies. GoFamer is a full-service technology company and expert partner in the constantly changing influencer marketing, sponsorship and digital marketing world, also known as the creator economy. GoFamer's platform solves multiple challenges facing creators and digital marketers by providing transparency and reliability to campaigns, aids in advancing online activities and generates reports with only a few clicks. The acquisition of GoFamer will complement Live Current Media's consumer facing digital platforms, including the popular video streaming platform Kast and augmented reality application Guru, by enabling the Company to offer creators a well rounded and highly unique value proposition in the digital and content marketing space integrated with flexible and intuitive creator monetization tools.

09:16 EST IAC reports November Angi Inc. total revenue up 5% from last year - As part of its November monthly metrics disclosure, IAC also reports Dotdash Meredith total pro-forma revenue down 27%, and its Search business revenue down 36% from last year. Emerging & Other revenue was up 15% from last year. Reference Link

09:14 EST Forward Air provided freight operating statistics for November - Forward Air provided the following expedited freight operating statistics for the quarter-to-date period through November. Shipments per day increased 2.4%, revenue per hundredweight increased 14.7%, while pounds per day decreased 11.9% and weight per shipment decreased 14% over the same period last year. At the same time, our customers and we are experiencing what we believe is a temporary but significant softening in the freight environment, with shipments significantly lighter due to 20% fewer pieces per shipment. The company's expectations regarding the company's performance in the fourth quarter and in any future period are based on information available at the time of this release, and are subject to changing conditions, many of which are outside of the company's control.

09:12 EST Blue Apron to reduce 10% of workforce, cut spend - Blue Apron released business updates regarding the funding status from affiliates of Joseph Sanberg, its expense reduction initiatives and its liquidity position. As previously disclosed, on November 6, Blue Apron entered into a pledge agreement under which one of Sanberg's affiliates pledged shares of private companies to the company to secure the private placement obligation of $56.5M of Class A common stock. As Sanberg's affiliate did not fund by November 30, under the agreement, the company now has the right to foreclose on the pledged collateral. While the company continues to assess the ability of Sanberg's affiliate to meet its obligations, Blue Apron is actively working with its financial advisors to maximize value from the pledged collateral, including potentially selling or leveraging the pledged collateral to enhance its credit with its current or future lenders. Blue Apron continues to identify and execute against multiple initiatives to both reduce expenses, and streamline decision-making and organizational structure, including a plan for meaningful reduction in marketing, consulting and labor spend in 2023. As such, to create a more nimble, focused organization and to better align internal resources with strategic priorities, Blue Apron is streamlining its personnel this week. This will result in a reduction of approximately 10% of its total corporate workforce. As a result of these actions, the company expects to incur approximately $1.2M in employee-related expenses, primarily consisting of severance payments, substantially all of which will result in cash expenditures. The company expects to recognize such expenses in the fourth quarter of 2022. Blue Apron plans to further reduce expenses and has identified expense reductions of up to approximately $50M in 2023, as compared to 2022, including the headcount changes identified above. These savings are planned to be implemented throughout the coming year. The cost reduction plans address both near-term and long-term expenses as Blue Apron focuses on driving towards profitability in the future. Including the expense reduction plans outlined above, Blue Apron is working to strengthen its balance sheet to maintain compliance with its $25M minimum liquidity covenant. The company plans to continue to execute on its at-the-market program, if market conditions permit, and execute on the additional planned expense reductions outlined above. With the ATM proceeds received to date, anticipated cost savings and working capital management, and without receipt of the private placement funds and funds owed under a gift card agreement with Sanberg's affiliate, Blue Apron believes it has sufficient cash flow to maintain compliance under its minimum liquidity covenant in the first quarter of 2023. In addition, if the company receives the private placement funds, funds owed under the gift card agreement, the full proceeds from its current ATM program, and is able to achieve the anticipated benefits of cost savings in 2023 as described above, the company believes it will have sufficient cash flow to maintain compliance under its minimum liquidity covenant into 2024. Blue Apron continues to work with its financial advisors to evaluate financing and other alternatives, in addition to being in discussions with its lender.

09:11 EST CNS Pharmaceuticals reports preliminary trial results of GBM candidate berubicin - CNS Pharmaceuticals announced preliminary results from its ongoing potentially pivotal trial evaluating Berubicin for the treatment of recurrent glioblastoma multiforme, or GBM. Preliminary results showed that the enrolled patients have comparable demographics, including age, gender, race, BSA and KPS and, in addition, the unmethylated MGMT population, which was approximately 40% in both arms. The percentage of patients that are currently continuing on study or having withdrawn is also comparable between arms. All grades of adverse events occurring in more than 5% of patients, as well as Grade 3-5 events, were also similar in the Berubicin and Lomustine arms. As of the data cutoff of October 17, 2022, 49 patients were enrolled in this potentially pivotal trial with 35 subjects on Berubicin and 14 subjects on Lomustine. A pre-planned, non-binding futility analysis of OS will be performed after approximately 30 to 50% of all planned patients are enrolled in the study. These patients will be evaluated at 6 months after enrollment in the study, which are expected mid-year 2023. This review will include additional evaluation of safety as well as secondary efficacy endpoints related to the efficacy of Berubicin. Enrollment will not be paused during this interim analysis.

09:08 EST Senmiao Technology partners with new energy vehicle infrastructure provider - Senmiao Technology's wholly owned subsidiary Sichuan Senmiao Zecheng has signed a strategic cooperation agreement with Chongqing Huicheng Future, a wholly owned subsidiary of Shenzhen Hifuture Information, listed on Shenzhen Stock Exchange. Huicheng Future specializes in Internet of Energy and related infrastructure, including the manufacture of smart electrical facilities and equipment, production and operation of charging piles, and construction and operation of charging infrastructure for new energy vehicles. Senmiao and Huicheng Future will begin collaboration on a new energy vehicle charging business by promoting the construction of new energy charging infrastructure in cities where Senmiao operates across China. Huicheng Future will provide Senmiao with favorable prices on equipment, construction and operations consulting services, equipment after-sales services, charging station construction, and technology upgrade and maintenance, among other services.

09:07 EST Datasea unveils Hailijia air sterilizer campaign - Datasea announced that it has unveiled the national Hailijia air sterilizer product campaign with an online event and offline product showcases in various cities in China, including Beijing, Shenzhen, Tianjin, Hangzhou and Shanghai. Hailijia air sterilizers and purifiers feature five different models to tackle a wide range of disinfection needs and have gained attention because of the global coronavirus pandemic. More than 50 institutions specializing in trade and distribution from China, Southeast Asia, and the Middle East participated in the event, highlighting the market interest in the products. During the product campaign, Datasea has entered into eight marketing and distribution agreements in order to expand the business and reach to customers and sell certain Hailijia air sterilizers and purifiers in China.

09:06 EST Fat Brands to make debut in Louisiana, North Texas - FAT Brands Inc., parent company of Fazoli's and 16 other restaurant concepts, announces two franchise development agreements to bring Fazoli's to Denton, Texas and Shreveport, Louisiana. Both the Denton, Texas location and the first of the two Shreveport, Louisiana locations are slated to open by the end of 2023. "Since integrating Fazoli's into the FAT Brands portfolio, we have been looking for the right strategic opportunities to grow the brand," said Taylor Wiederhorn, Chief Development Officer of FAT Brands. "Texas continues to be a market that we are focused on across the board, so we are excited to add another brand of ours in the Dallas-Fort Worth area. Similarly, another key area of emphasis is expanding with our existing franchisee base. Chris and Kristen Simmons are long-time Marble Slab Creamery operators in Louisiana who saw the value in diversifying the concepts they are operating under FAT Brands."

09:05 EST Trivago becomes official partner of IHR Men's World Handball Championship 2023 - trivago announced an official partnership with the 2023 Men's IHF World Handball Championship, furthering its purpose of empowering people to get more out of life. As the official Online Travel partner of the IHF Men's World Championship 2023, trivago branding will appear during matches in January 2023 and throughout the competition. The global tournament will be held in Sweden and Poland from January 11 to 29, 2023, and has an expected viewing audience of over 1.2 billion, with an estimated 1 million total spectators attending live. "The handball World Cup is a unique opportunity for thousands of fans to meet and celebrate," says trivago CEO Axel Hefer. "The competition shows that sport and travel have a common goal: bringing people together! We believe that this partnership with the International Handball Federation is a great match for trivago." This new sponsorship is an expansion of trivago's commitment to the common values of sport and travel.

09:05 EST Sidus Space announces plan to increase presence in Europe - Sidus Space announced plans to increase its presence in Europe by opening a new office in the Netherlands. Sidus plans to expand its reach in the European market to engage the rapidly growing space ecosystem and promote space-based data adoption by democratizing access to space. As part of its international expansion, Sidus Space previously announced agreements with Dawn Aerospace, GTM and Dhruva Space and continues to explore opportunities with other international customers in the government and commercial sectors. In addition, CEO Carol Craig and members of the Sidus Space team participated in multiple international Space industry conferences over the last several months and provided capabilities presentations to several international delegations including Turkey, France, Spain and Japan.

09:04 EST Nucor makes equity investment in Electra - Nucor announced that it has made an equity investment in Electra, a Colorado-based start-up developing a process to produce carbon-free iron that can be used to make steel. The company uses renewable energy to refine low-grade iron ores into high-purity iron through electrochemical and hydrometallurgical processes. This material will be used in the steelmaking process to offset other high-quality metallics that come with higher greenhouse gas emissions.

09:04 EST Maris-Tech announces $3.4M of order backlog as of January 1, 2022 - Maris-Tech announced that the Company's order backlog, as of January 1, 2022, is approximately $3,360,000, of which approximately $968,000 was delivered and recognized as revenue during the six months ended June 30, 2022, approximately $364,000 has been delivered to customers from July 1,2022 through December 7, 2022, and the majority of the approximately $2,028,000 remaining is expected to be delivered and recognized as revenue by June 30, 2023. The Company's order backlog is the accumulation of all pending orders with a later fulfillment date for which the Company considers valid, in addition to recognized revenues since January 1, 2022 and for products delivered since July 1, 2022, which revenue has not been recognized as of December 7, 2022. The order backlog includes orders for the Company's latest and advanced Jupiter products family, including the Jupiter-nano and the Jupiter AI multiple-stream video platform with edge artificial intelligence acceleration. Israel Bar, Chief Executive Officer of Maris-Tech, said "We have been witnessing a growing demand for high-quality video transfer capabilities and uncompromising speed for some time. Thanks to our ability to meet these needs, we acquired strong, quality customers from a variety of industries, including the aerospace industry, in which suppliers are very carefully selected. We believe the future looks very promising for the Company, as we expect the demand for our products to continue to increase."

09:03 EST Y-mAbs' DANYELZA for treatment of high-risk neuroblastoma approved in China - Y-mAbs Therapeutics announced that the National Medical Products Administration, NMPA, in China has granted DANYELZA 40mg/10ml conditional approval. DANYELZA will be marketed in China by Y-mAbs' partner SciClone Pharmaceuticals. DANYELZA is indicated, in combination with granulocyte-macrophage colony-stimulating factor, for the treatment of pediatric patients 1 year of age and older and adult patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow who have demonstrated a partial response, minor response, or stable disease to prior therapy. Continued approval for this indication may be contingent upon verification and description of clinical benefits in a confirmatory trial, Study 201, where no less than 10 patients shall be enrolled in China. "Today is an important day for children living with refractory/relapsed high-risk neuroblastoma in China. It's very exciting to see this treatment conditionally approved in such a substantial territory after a solid joint effort by our Chinese partner SciClone Pharmaceuticals and the development team at Y-mAbs," said Thomas Gad, founder, President and Interim CEO.

09:02 EST Sumo Logic announces availability of Cloud SOAR in AWS Tokyo region - Sumo Logic announced the availability of Sumo Logic Cloud SOAR in the AWS Tokyo region. It marks the second Sumo Logic security solution now available in the region and the latest move by Sumo Logic to ensure efficient global growth throughout the Asia-Pacific region. Last year, Sumo Logic delivered Sumo Logic Cloud SIEM to Japan, Australia and India. With Cloud SOAR now available, Sumo Logic delivers access to its award-winning automation solution designed to improve incident response time, enhance visibility and improve collaboration across security operations.

08:56 EST SOBR Safe signs SaaS agreement with oilfield services, logistics provider - SOBR Safe announced that its recent multi-site SOBRcheck trials for the oil and gas industry were successful, yielding a signed software as a service agreement with a leading oilfield services and logistics provider. The provider serves all major US oilfield basins and is initially installing SOBRcheck in two of its numerous service centers, for both fleet and workplace applications.

08:54 EST Critical Elements appoints Andy Fortin as senior process, commissioning manager - Critical Elements Lithium announced the appointment of Mr. Andy Fortin, Metallurgical Engineer, as Senior Process and Commissioning Manager. He has been involved in numerous projects in process design, commissioning to achieve production capacity and operational improvement, notably with Quebec Iron Ore, Newmont / Goldcorp, Agnico-Eagle Mines and Inmet Mining Corporation.

08:52 EST Allbirds names Kate Ridley chief brand, product officer - Allbirds announces promotions within its Executive Leadership Team. Kate Ridley, Allbirds's Chief Brand Officer, has been promoted to Chief Brand and Product Officer and Benny Joseph, Allbirds's Chief Technology Officer, has been promoted to Chief Technology and Culture Officer. Concurrent with Ms. Ridley's promotion, Co-CEO Tim Brown will expand his focus to include leadership of Allbirds's Innovation Futures team, which encompasses Innovation and Sustainability. This team's mandate is to ideate and source future innovation that will help shape the next generation of Allbirds's sustainable product. Tim will also dedicate more time to external communications and building partnerships to amplify brand messaging, as well as Allbirds's positioning as an industry leader in sustainability.

08:50 EST Ivanhoe Electric's Cordoba signs milestone agreements with JCHX - Ivanhoe Electric's subsidiary, Cordoba Minerals and JCHX Mining Management have agreed to a strategic arrangement for the joint development of Cordoba's flagship Alacran Project in Colombia. Ivanhoe Electric owns a 63.27% interest in Cordoba. Key terms of the milestone agreements signed on December 7, 2022: JCHX, through a wholly owned subsidiary, will purchase a 50% ownership interest in CMH Colombia, a company existing under the laws of Colombia, for aggregate consideration of $100 million. CMH will own 100% of the Alacran Project and will be the joint venture vehicle for Cordoba and JCHX in this strategic project level partnership. JCHX will satisfy the purchase price of $100 million as follows: At the closing of the transaction, which is expected to occur before the end of the first quarter of 2023, $40 million will be payable in cash. A second installment of $40 million is payable in cash upon completion of a Feasibility Study of the Alacran Project and the submission of the Environmental Impact Assessment to the relevant Colombian Government authority. A third and final installment of $20 million is payable in cash once the approval of the EIA is obtained, which must be within two years of the transaction's closing date. Should the EIA not be approved by the second anniversary of the closing date, JCHX will have the option to elect not to complete this final installment, which will result in JCHX being diluted to 40% and Cordoba increasing to a majority 60% shareholding in CMH. JCHX will advance a bridge loan of $10 million in cash to Cordoba, which is expected to be funded prior to the end of December 2022, following the signing of these milestone agreements and conditional upon JCHX shareholder approval. Upon closing of the transaction, the entire balance owing under the bridge loan and accrued interest will be applied towards the first installment payment as a payment in kind. Closing of this transaction is subject to: FOR CORDOBA: Approval from the TSX Venture Exchange and approval of shareholders; FOR JCHX: Approval from the Board of Directors, shareholders, China's State Administration of Foreign Exchange, and Beijing Municipal Bureau of Commerce. The bridge loan comes into effect immediately upon execution of a bridge loan agreement, with the advance occurring immediately after approval from the JCHX board and shareholders, which is expected to occur by the end of December 2022. The remainder of the transaction agreements do not become effective until JCHX obtains shareholder approval, which is expected in mid-January 2023. Cordoba will repay $2.5 million of the short-term loans that were previously provided by Ivanhoe Electric, upon receiving the $10 million bridge loan from JCHX. All outstanding amounts of the short-term loans will be repaid to Ivanhoe Electric, with interest, upon the closing of the transaction and the receipt of the $40 million installment from JCHX, which is expected to occur before the end of the first quarter of 2023. Key decisions to be governed by a Joint Venture Shareholders' Agreement: A Joint Venture Shareholders' Agreement will govern the strategic relationship between Cordoba and JCHX, and will set forth the general responsibility and authority of the CMH board of directors, in addition to the entitlements of each shareholder. The JV SHA which will be entered at closing, provides for among other things: The CMH board will comprise of four individuals, of which two directors will be nominated by Cordoba and the other two directors will be nominated by JCHX; and for so long as the shareholdings in CMH remain 50%-50%, a Cordoba representative will serve as the Chairperson of the Board of Directors, and will possess a casting vote on all matters subject to a list of reserved matters. Cordoba will be appointed as the operator and manager of the Alacran Project pursuant to a management services agreement and will be responsible for setting the annual programs and budgets for the CMH board's approval. JCHX has right of first offer to bid on the Engineering, Procurement and Construction and Detailed Design Agreement contracts, provided that Cordoba has the right to open the process out to competitive tender; with JCHX having the right to match any competitive bid. JCHX shall be entitled to up to 100% of the offtake from the production under the current Feasibility Study of the Alacran Project, provided that they are paying fair market value and they are the most competitive offer.

08:49 EST GE HealthCare says 'strong opportunities ahead' for each segment - Says ability to keep name of GE HealthCare was a "big deal" in terms of brand equity. Says "uniquely positioned" to grow in precision care. Says "super excited" about what precision care can be in near future.

08:49 EST Ciena sees FY23 gross margin 42%-44%

08:47 EST Ciena plans to repurchase shares in FY23 in the range of $250M, says CFO

08:41 EST AcelRx's sufentanil tablets for post-operative pain featured in publication - AcelRx announced a recent retrospective study published in the Journal of Clinical Medicine Special Issue which retrospectively analyzed a total of 71 patients with respect to quality of postoperative pain management following total knee arthroplasty. Investigators analyzed data from 50 patients who received sufentanil sublingual tablets, or SSTs, postoperatively versus a control group of 21 patients who were treated according to standard pain management protocol with continuous femoral nerve block. NRS scores were statistically lower in the SSTs group compared to the control group 24 hours following surgery, and numerically lower at all other time points. Fewer patients in the SSTs group required rescue analgesic doses - 5% - vs. control group - 60% - and discharge occurred on average 1.5 days earlier in the SSTs group. Adverse events were noted as being consistently lower in the group administered SSTs, and this was most notably observed to be the case with nausea - 10% vs. 30%- , typically the most frequently reported adverse event with postoperative opioid administration.

08:41 EST Ciena sees 'outsized' y/y revenue growth in FY23, consensus $4.04B

08:40 EST Ads-Tec Energy enters strategic partnership with GP Joule Connect - ADS-Tec Energy announced a strategic partnership with sustainable mobility solutions company GP Joule Connect a systems provider for new mobility. As part of the collaboration, GP Joule Connect will be deploying 30 ADS-TEC Energy ChargePost and 10 ChargeBox systems in 2023. Both companies aim to actively drive the expansion of charging infrastructure as well as the transformation of energy systems and jointly plan to build numerous battery storage-based, ultra-fast charging stations in Germany and elsewhere in Europe.

08:39 EST AstraZeneca reports results from SERENA-2 trial - Detailed results from the SERENA-2 Phase II trial showed AstraZeneca's next-generation oral selective estrogen receptor degrader camizestrant demonstrated a statistically significant and clinically meaningful improvement in progression-free survival, or PFS, at both 75mg and 150mg dose levels versus Faslodex 500mg in post-menopausal patients with estrogen receptor, or ER-positive locally advanced or metastatic breast cancer, previously treated with endocrine therapy. Results will be presented in an oral presentation at the San Antonio Breast Cancer Symposium. In the overall population, camizestrant significantly reduced the risk of disease progression or death by 42% at a 75mg dose and 33% at a 150mg dose compared to Faslodex, the current SERD standard of care. Among the prespecified subgroup of patients with ESR1 mutations - comprising 36.7% of the trial population - camizestrant showed a 67% reduction in the risk of disease progression or death at a 75mg dose and a 45% reduction at a 150mg dose compared to Faslodex. Efficacy was also seen in patients without a detectable ESR1 mutation, with a 22% and 24% reduction in the risk of disease progression or death respectively for the 75mg and 150mg dose levels. A clinically meaningful PFS benefit was also observed across other prespecified subgroups, including in patients with previously treated with prior cyclin-dependent kinase 4/6 inhibitors, those with lung and/or liver metastases and those with ER-driven disease.

08:38 EST Recon Technology awarded RMB3.97 contract for heating furnaces equipment - Recon Technology announced that a mainland China variable interest entity's subsidiary, Huang Hua BHD Petroleum Equipment Manufacturing, was awarded a RMB3.97M or $0.57M contract to provide high efficiency heating furnaces equipment for a China oil and gas company. In total, HH BHD has generated RMB6.68M, or $0.96M, in revenue from awarded bids and contracts in the past fiscal quarters. The equipment HH BHD will supply includes insulation devices, automatic alcohol injection device for oil and gas wells and pipelines, large tank extraction skids for processing equipment, splitters and sewage tanks.

08:37 EST Inspirato announces JauntLiving extended stays feature - Inspirato announced the launch of JauntLiving, a new members-only benefit featuring significant savings on extended stays in Inspirato luxury vacation homes. JauntLiving stays range from 14 days to a year in length, are available in top destinations throughout the Inspirato portfolio, feature flat rate all-inclusive pricing, and include Inspirato's personalized five-star service. With JauntLiving, Inspirato members can easily book a multi-month spring golfing hiatus in sunny Los Cabos, move into their own place in the Hamptons for the summer, watch the aspens change in Vail all autumn long, or luxuriate for months resort-style overlooking the Pacific in Newport Beach. In each case, Inspirato's expert on-site concierge teams will be on hand to help members "live local" during their stays, guiding them to the best their destination has to offer, while providing the exceptional service and certainty for which Inspirato is known.

08:36 EST Kearny Financial targets 5%-10% annualized reduction in operating expense - Given the prevailing economic and interest rate environment, the Company has also embarked upon a company-wide operating efficiency initiative, targeting an annualized reduction in operating expense of five to ten percent. The goal of this initiative is to improve the Company's cost structure through cost-reduction and cost-containment initiatives. These include actions surrounding the optimization and reduction of vendor spend, the automation or outsourcing of routine activities, and the realignment of the Company's workforce.

08:35 EST Kearny announces wholesale restructuring, operating efficiency initiative - Kearny Financial announced the completion of a wholesale restructuring related to its investment securities portfolio. In addition, the Company announced the adoption of a company-wide operating efficiency initiative. The Company executed the sale of $121.4 million of its lower-yielding available-for-sale debt securities for an estimated after-tax loss of approximately $11.0 million. Proceeds from the sale were reinvested in debt securities currently yielding, on average, 440 basis points higher than the securities that were sold. In addition, the Company purchased approximately $100.0 million of debt securities, funded by wholesale borrowings, which will produce an average spread of 216 basis points. The loss on sale of securities is expected to have a nominal impact on tangible book value, as such loss was previously reflected in capital through accumulated other comprehensive loss. Given the prevailing economic and interest rate environment, the Company has also embarked upon a company-wide operating efficiency initiative, targeting an annualized reduction in operating expense of five to ten percent. The goal of this initiative is to improve the Company's cost structure through cost-reduction and cost-containment initiatives. These include actions surrounding the optimization and reduction of vendor spend, the automation or outsourcing of routine activities, and the realignment of the Company's workforce.

08:34 EST Stem announces four 9.9 MW standalone energy storage projects - Stem announced four 9.9 megawatts, or MW, standalone energy storage projects in Texas with REX Storage Holdings, an independent power producer focused on standalone battery energy storage systems for Ercot power customers. Rex is a joint venture between Regis Energy Partners, an independent developer, owner, and operator of energy storage systems, and Excelsior Energy Capital, or EEC, an investment fund focused on renewable power generation. The projects represent the first of a $400M equity commitment by REX to acquire additional construction-ready projects from Regis' development pipeline within the Electric Reliability Council of Texass territory, power supplier to more than 26M customers representing approximately 90% of the state's electric load.

08:34 EST Latin Metals provides update on Barrick Gold exploration activities - Latin Metals provides an update on exploration at the Cerro Bayo project, located in the Deseado Massif, Santa Cruz Province, Argentina. Cerro Bayo is subject to an earn-in agreement with a wholly-owned subsidiary of Barrick Gold Corporation. Under the terms of the Earn-In Agreement, Barrick has the right to acquire up to an 85% interest in the Project. To date, Barrick has completed a substantial amount of surface exploration at Cerro Bayo, including a 1,000-line-km ground magnetic survey, geological mapping, rock sampling and spectral analysis. The ground magnetic survey covers approximately 95% of the property and confirms an important property-wide northwest trending structural fabric, which is potentially favourable to hosting gold and silver mineralization. Geological mapping of the property has been carried out at a scale of 1:10,000, and more detailed district-scale alteration mapping is in progress, supported by spectrometry data collection. Favorable structures for mineralization, including veinlets, brecciated veins, and fault breccias have been recognized. This mapping has demonstrated that northwest-trending structures are controlling gold and silver mineralization and it has established the presence of intrusive and subvolcanic bodies, which may provide a heat source for hydrothermal fluids at Cerro Bayo. Rock samples were collected following the orientation of the most prospective structures. A total of 729 rock chip samples have been taken to date and the sampling has been completed across the entire Cerro Bayo property, with results pending on 159 samples. Top-5% of silver and gold samples received to date have been used to highlight the most anomalous areas at Cerro Bayo.

08:32 EST WPP acquires Diff, terms undisclosed - WPP announced that it is acquiring Diff, a commerce agency based in Montreal, Canada. Diff is a developer of tailor-made commerce solutions with specialized capabilities that address the rapidly growing Shopify commerce ecosystem. Founded in 2011 by Benjamin Crudo, the 115-person company will join the Wunderman Thompson global network, complementing its commerce and marketing services teams in North America.

08:30 EST T2 Biosystems highlights peer-reviewed article on COVID-19, sepsis - T2 Biosystems announced the publication of a peer-reviewed article published by Oxford University Press on behalf of the Infectious Diseases Society of America. "We are grateful to these distinguished authors for reinforcing the CDC's call for adoption and implementation of early and accurate microbial diagnosis to guide targeted antimicrobial treatment, directly aligning with the value proposition of T2's technology," stated John Sperzel, Chairman and CEO of T2 Biosystems. "Sepsis continues to exact a heavy human and financial toll, and disproportionally impacts minorities and underserved communities. We believe our FDA-cleared T2Dx Instrument, T2Bacteria Panel, and T2Candida Panel can help advance the standard of care and offer the ideal solution to rapidly and accurately detect sepsis-causing pathogens and provide the information required to allow clinicians to achieve faster, targeted antimicrobial therapy." Title: Meeting the Challenges of Sepsis in Severe COVID-19: A Call to Arms: This perspective reviewed the burden of bacterial and fungal sepsis from epidemiological and personal viewpoints, and highlighted the convergence of risk factors and clinical manifestations of severe COVID-19 and sepsis posing a daunting bedside challenge to accurate diagnosis. Article Highlights: The global burden of sepsis, from any cause, is estimated to be 50 million cases per year and is the cause of 1 in 5 deaths, including approximately 350,000 Americans and 680,000 Europeans each year; The U.S. spends an estimated $62 billion annually on sepsis treatment making it the most expensive in-hospital therapeutic cost; Sepsis is a severe health hazard requiring timely and appropriate therapy; survival decreases by 7.6% for each hour of delay in providing appropriate therapy; Critically-ill hospitalized patients with SARS-CoV-2 infections are at increased risk for secondary bacterial and fungal infections; By improving outcome of sepsis, the disparate outcomes from COVID-19 in historically disadvantaged minorities may also be improved; Indigenous Americans, Pacific Island Americans, and Black Americans have the highest mortality rates from COVID-19 infections; While administration of broad spectrum antimicrobial therapy in the absence of a microbial diagnosis is the standard of care in the empirical management of sepsis, the strategy is also associated with adverse events and selection of resistant pathogens; Rapid diagnostics must be deployed for use and be accessible for use across all segments of the health care system, to shorten the lag from time of exposure to appropriate and targeted therapy, reduce the likelihood of administration of unnecessary drugs, improve outcomes, lower health care costs, shorten hospital length of stay, and reduce the probability of developing antimicrobial resistance; Underscores the CDC call for the adoption and implementation of early and accurate microbial diagnosis to guide targeted antimicrobial therapy.

08:26 EST Nuwellis adjourns special meeting of stockholders - Nuwellis announced that the Company's Special Meeting of Stockholders, on December 7, 2022 at 2:00 p.m., was convened and adjourned, without any business being conducted, due to lack of the required quorum. A quorum consists of one-third of the outstanding shares entitled to vote. There were fewer than one-third of outstanding shares entitled to vote, either present virtually or represented by proxy, at the Special Meeting. The Special Meeting therefore had no quorum and was adjourned to 2:00 p.m. Central Time on January 4, 2023 at www.viewproxy.com/nuwesm/2022 to allow additional time for the Company's stockholders to vote on the proposals set forth in the Company's definitive proxy statement filed with the Securities and Exchange Commission on November 7, 2022. During the period of adjournment, the Company will continue to solicit votes from its stockholders with respect to the proposals set forth in the proxy statement. Only stockholders of record as of the record date, October 13, 2022, are entitled to and are being requested to vote. At the time the Special Meeting was adjourned, proxies had been submitted by stockholders representing approximately 31.69% of the shares of the Company's common stock outstanding and entitled to vote at the Special Meeting. Proxies previously submitted in respect of the Special Meeting will be voted at the adjourned Special Meeting unless properly revoked, and stockholders who have previously submitted a proxy or otherwise voted need not take any action.

08:24 EST Intra-Cellular highlights CAPLYRA bipolar depression data - Intra-Cellular Therapies announced four data presentations at the American College of Neuropsychopharmacology 61st Annual Meeting highlighting the therapeutic use of CAPLYTA for the treatment of bipolar I and II depression. Monday December 5: Poster M78: "Metabolic Profile of Lumateperone in Late-Phase Clinical Trials for the Treatment of Major Depressive Episodes Associated With Bipolar I or Bipolar II Disorder": This poster presents a comprehensive weight and metabolic analysis of more than 1,200 patients that participated in our lumateperone late-stage bipolar depression program: two 6-week monotherapy and one 6-week adjunctive therapy placebo-controlled studies and a 6-month open label extension safety study. The results demonstrate that in patients with bipolar I or bipolar II disorder experiencing a major depressive episode, lumateperone 42-mg monotherapy or adjunctive therapy had a favorable cardiometabolic profile for both acute and long-term treatment. The results confirm the favorable effects of lumateperone 42mg on body weight and morphology as demonstrated by minimal and similar to placebo mean changes from baseline in weight, BMI and waist circumference in short-term studies and no increases seen in these parameters in the long-term OLE study. In addition, potentially clinically significant weight changes were assessed. In the short-term studies, no patients treated with lumateperone had PCS weight gain during treatment and, in the long-term OLE study, PCS weight loss was more common than PCS weight gain. Consistent with prior analyses, mean changes in key cardiometabolic parameters including fasting glucose, insulin, total cholesterol and triglycerides, were all similar to placebo. There were no clinically significant changes in these parameters in the long-term OLE study. Poster V19: "Efficacy of Lumateperone in Pooled Short-Term Late-Phase Clinical Trials for the Treatment of Major Depressive Episodes Associated With Bipolar II Disorder": This poster describes a pooled analysis of the efficacy of lumateperone 42 mg monotherapy and adjunctive therapy across three short-term, placebo-controlled Phase 3 studies in a subgroup of patients with depressive episodes associated with bipolar II disorder. The results demonstrate that in patients with bipolar II disorder experiencing a MDE, lumateperone 42-mg monotherapy or adjunctive therapy significantly improved symptoms of depression and disease severity compared with placebo. In patients with bipolar II disorder, lumateperone 42 mg significantly improved the Montgomery-Asberg Depression Rating Scale total score from baseline to week 6 compared with placebo. A higher proportion of bipolar II patients on lumateperone had a treatment response compared with placebo. Lumateperone significantly improved illness severity at week 6 as measured by the clinical global impression scales of severity. Further, there was significant improvement on the Quality-of-Life Enjoyment and Satisfaction Questionnaire - Short Form as compared to placebo. Poster V21: "Evaluation of Mania and Hypomania in Late-Phase Clinical Trials of Lumateperone in the Treatment of Major Depressive Episodes Associated With Bipolar I or Bipolar II Disorder": When treating patients with bipolar depression, switching to mania/hypomania represent important treatment-emergent adverse events to monitor. This poster presents analyses of measures of mania and hypomania across our short-term, placebo-controlled studies and long-term OLE study of lumateperone in patients with a MDE associated with bipolar I or bipolar II disorder. The poster highlights that the incidence of mania/hypomania events were similar between lumateperone 42 mg and placebo. Across short-term trials, the incidence of mania/hypomania TEAEs were rare, and if occurred, were mild or moderate in severity and similar between lumateperone and placebo. These TEAEs were also rare and mild or moderate in severity in the long-term OLE study. There were no notable changes from baseline in mean Young Mania Rating Scale. Total score in short-term, placebo-controlled studies and the long-term OLE study. Mean changes in CGI-BP-S Mania subscore were similar between lumateperone and placebo in short term trials and remained clinically stable throughout the long-term OLE study. Poster W79: "Lumateperone in the Treatment of Major Depressive Episodes Associated With Bipolar I or Bipolar II Disorder: Evaluation of Extrapyramidal and Motor Symptoms in Late-Phase Clinical Trials": Lumateperone is a simultaneous modulator of serotonin, dopamine, and glutamate neurotransmission with low D2 receptor occupancy at the recommended dose of 42mg. Elevated levels of dopamine D2 occupancy are known to be associated with increases in extrapyramidal symptoms. This poster describes the incidence of EPS across our short-term, placebo-controlled studies and long-term OLE study of lumateperone in patients with a MDE associated with bipolar I or bipolar II disorder. The incidence of EPS-related TEAEs was low and mild or moderate in severity across short-term trials and the long-term OLE study. The use of concomitant benztropine and propranolol was rare. There were no notable changes from baseline in clinician-rated motor scale scores. The incidence of treatment-emergent parkinsonism and akathisia in the short-term, placebo-controlled studies was similar to placebo and was minimal in the OLE. In patients with bipolar I or bipolar II disorder experiencing a MDE, lumateperone 42-mg had a favorable EPS profile in both acute and long long-term treatment.

08:21 EST INmune Bio to present data from UK patients treated with INKmune - INmune Bi will present data from UK patients with MDS or AML treated with INKmune at the annual American Society for Hematology, ASH, Conference held in New Orleans December 10th - 13th. The poster presents findings from patients who have received INKmune therapy for treatment of their AML/MDS and provides additional information on the biologic changes that occur in the patients' NK cells after treatment with INKmune. Highlights include: INKmune safely administered to 4 patients without SAE/R. Demonstrable and sustained NK activation in 3 of the 4 patients. Patient 4 had a high level of disease with low numbers of NK cells of which more than half her NK cells were immature. Persistent tumor killing memory-like NK cells in the patient with MDS for more than 100 days. NK activation temporally associated with significant changes in systemic levels of key cytokines including Macrophage Inflammatory Proteins. INKmune activated NK cells show proteomic and metabolomic changes predictive of improved survival in the tumor microenvironment. The Laurel Phase I trial continues to enroll patients in the UK and EU with two new sites in the process of opening recruitment. In addition, the Company is preparing to expand the INKmune program to the US in a solid tumor indication. The Company will make additional announcements regarding the solid tumor target and the timing of the clinical trial. "Presentation of data at the most important hematologic cancer meeting is an honor. We hope this will be the first of many presentations on this promising program," said RJ Tesi, MD, CEO of INmune Bio. "The ability of INKmune primed NK cells to survive and thrive in the hypoxic and immunologically hostile TME is unique. This biology makes a pivot to INKmune treatment of solid tumors an obvious next step in the platform's growth."

08:20 EST Alimera Sciences agrees to amend existing loan, security agreement - Alimera Sciences (ALIM) announced that it has agreed to an amendment to its existing loan and security agreement with its debt facility partner, SLR Investment Corp (SLRC) to extend the interest-only period through March 31, 2023 with the possibility of extending to July 1, 2023.

08:19 EST iCAD features Solis Mammography in 'ProFound Insights, ProFound Impact' webinar - iCAD announced Solis Mammography will be featured in the next "ProFound Insights, ProFound Impact" webinar, on Dec. 14 at 3 pm EST / 12 pm PST. Moderated by iCAD's President and CEO, Stacey Stevens, the event will feature an exclusive interview with Chirag Parghi, M.D., Chief Medical Officer, Solis Mammography, who will share best practices and real-world case studies demonstrating the clinical value of ProFound A, iCAD's flagship artificial intelligence solution for breast imaging. Solis Mammography was an early adopter of iCAD's suite of Breast AI solutions, including ProFound AI, the first solution of its kind to be FDA cleared, integrating the technology into its early detection screening platform in spring 2021. During the event, Dr. Parghi will share the company's experience deploying this technology across its network of centers.

08:17 EST Immutep achieves commercial scale in manufacturing of eftilagimod alpha - Immutep (IMMP) announces the successful scale-up of the manufacturing of its lead product candidate eftilagimod alpha, a first-in-class soluble LAG-3 protein, with the completion of a 2,000L manufacturing run. In preparation for late-stage clinical trials and commercial production, Immutep has been working with WuXi Biologics (WXXWY) to increase the efti manufacturing process from 200L to 2,000L capacity single-use bioreactors at the manufacturing plant in Wuxi city, China. The first 2,000L manufacturing run has been performed successfully with all predefined release criteria met. Marc Voigt, CEO of Immutep said: "Following compelling results from the TACTI-002 Phase II trial and promising initial clinical data from INSIGHT-003 recently presented at SITC 2022, we are pleased to announce this significant achievement reaching commercial scale in efti's manufacturing by WuXi Biologics, an important long-term partner of Immutep. With potential registrational trials in multiple indications for our first-in-class soluble LAG-3 protein, including our ongoing randomised TACTI-003 Phase IIb trial in 1st line head and neck cancer, this represents an important step towards potential commercial production of efti."

08:16 EST Osisko Gold announces TSX approval to renew normal course issuer bid - Osisko Gold Royalties announces that the Toronto Stock Exchange has approved the Corporation's notice of intention to make a normal course issuer bid. Under the terms of the NCIB Program, Osisko may acquire up to 18,293,240 of its common shares from time to time in accordance with the normal course issuer bid procedures of the TSX. The normal course issuer bid will be conducted through the facilities of the TSX or through alternative trading systems in Canada, if eligible, and will conform to their regulations. Purchases under the normal course issuer bid will be made by means of open market transactions or such other means as a securities regulatory authority may permit, including pre-arranged crosses, exempt offers and private agreements under an issuer bid exemption order issued by a securities regulatory authority. Repurchases under the NCIB Program may commence on December 12, 2022 and will terminate on December 11, 2023 or on such earlier date as the NCIB Program is completed. Daily purchases will be limited to 81,963 Common Shares, other than block purchase exemptions, representing 25% of the average daily trading volume of the Common Shares on the TSX for the six-month period ending November 30, 2022, being 327,853 Common Shares. The price that the Corporation may pay for any Common Shares purchased in the open market under the NCIB Program will be the prevailing market price at the time of purchase (plus brokerage fees) and any Common Shares purchased by the Corporation will be cancelled. In the event that the Corporation purchases common shares by pre-arranged crosses, exempt offers, block purchases or private agreements, the purchase price of the common shares may be, and will be in the case of purchases by private agreements, as may be permitted by the securities regulatory authority, at a discount to the market price of the common shares at the time of the acquisition. The board of directors of Osisko believes that the underlying value of the Corporation may not be reflected in the market price of the Common Shares from time to time and that, accordingly, the purchase of Common Shares will increase the proportionate interest in the Corporation of, and be advantageous to, all remaining shareholders of the Corporation.As of November 30, 2022, there were 183,921,409 Common Shares issued and outstanding. The 18,293,240 Common Shares that may be repurchased under the NCIB Program represent approximately 10% of the public float of the Corporation as of November 30, 2022, being 182,932,406 Common Shares. During the prior NCIB Program of the Corporation, which will end on December 11, 2022, the Corporation obtained approval to purchase 16,530,688 Common Shares and actually purchased 1,694,658 Common Shares at a weighted average price of approximately $13.0619 per Common Share through the facilities of the TSX and through alternative trading systems in Canada.

08:15 EST Forward Air announces 5.9% general rate increase - Forward Air announced a 5.9% general rate increase, or GRI, on any shipments tendered on or after February 6, 2023. The company believes the rate changes will enable it to continue investing in service enhancement as operating costs have risen by double digit percentages in 2022 for many in the freight transportation industry. Factors necessitating the GRI include increased costs in real estate, equipment, cost per mile and economic inflation. As an expedited carrier, the Forward operates on demand without the long lead times that traditional carriers require. Forward remains committed to providing best-in-class, premium expedited service to its customers.

08:14 EST Ramaco Resources sees 2023 production 3.0-3.5 million tons - The company expects to ship near current levels in 1Q23, with a material increase by mid-year when the Elk Creek preparation plant processing capacity expansion becomes fully operational. The expansion will take the complex from a 2 million ton per year run rate to 3 million ton per year run rate. In addition, and in line with previous expectations, the company expects the Berwind No.1 mine to return to production by April 1, 2023. Ultimately the cCompany anticipates its 2023 shipments will exceed production by roughly 200,000 tons due to shipping inventory built during 2022.

08:13 EST Mullen Automotive hires Borthwick as VP of Commercial Sales - Mullen Automotive announces the hiring of Donald Borthwick as its Vice President, VP, of Commercial Sales. Borthwick, with over 25 years leading commercial vehicle sales for Ford, will spearhead Mullen's commercial vehicle sales for the U.S. Borthwick will be established out of the recently opened Mullen Tech Center, located in Troy, Michigan.

08:12 EST ProSomnus announces puublication on intraoral medical devices in OSA - ProSomnus announced the publication of a peer-reviewed, independent, study in Military Medicine, in which 88% of patients with Obstructive Sleep Apnea were successfully treated using the Company's novel precision intraoral medical devices. Following approval from the Carl R. Darnall Army Medical Center Institutional Review Board and the Defense Health Agency, the investigators analyzed the records of active-duty military patients treated for OSA to determine the success of precision oral appliance therapy based on a symptom-driven titration. The study demonstrated that 88% of patients were successfully treated with precision OAT to an Apnea-Hypopnea Index of less than 10 events per hour, which was noted as better than previous studies that utilized non-precision, dental products. The study also reported statistically significant improvements in respiratory disturbances, oxygen saturation, REM sleep, sleep efficiency and daytime sleepiness, with a 79.6% mean reduction in sleep apnea events. For context, previous studies reported that success rates with traditional, non-precision, OAT were less than 65%.

08:11 EST Splash Beverage's TapouT receives authorization to be sold in Publix stores - Splash Beverage Group announced that it has received authorization from Publix for all four TapouT SKU's to be sold in Publix stores across 5 southeastern U.S states. Robert Nistico, Splash Beverage Group's Chairman and CEO commented, "We continue to establish TapouT as a rising consumer choice with this latest top tier authorization. With previous authorizations from Winn Dixie and Walmart, this authorization from Publix means that TapouT will now be available and at arm's reach in most grocery retailers throughout the Southeast U.S. Additionally, we believe this authorization will drive new distribution opportunities for the brand as some distributors that cover these stores do not yet sell TapouT. We very much look forward to working with Publix and expanding on this relationship."

08:10 EST Ramaco Resources increases cash dividend 10% to 12.5c per share - Ramaco Resources approved a 10% increase in its cash dividend. The Board of Directors declared a quarterly cash dividend of 12.5c per share of common stock payable in 1Q23, up from 11.33c per share of common stock in 4Q22. The Q1 dividend is payable on March 15, 2023, to shareholders of record on March 1, 2023.

08:09 EST AIM ImmunoTech reports safety, tolerability, biological data for Ampligen - AIM ImmunoTech reported that data were recently presented by Lisanne C.A. Smidt - Centre for Human Drug Research, CHDR, Leiden, the Netherlands in a poster titled, "Safety, tolerability and biological activity of repeated intranasal administration of TLR3 agonist Ampligen in healthy subjects," at the British Society for Immunology Congress 2022 . The data showed positive safety, tolerability and biological activity of a 13-day dosing regimen conducted in Q2 2021 for intranasal Ampligen in healthy subjects. The study found: Repeated intranasal administration of Ampligen was well tolerated. No severe or serious AEs reported; Solicited local AEs were comparable across all treatment groups and placebo; An increase in IL-6, IL-8, and TNF production was observed for both Ampligen and placebo after dosing; MCP-1 and RANTES - which are important immunomodulators - peaked 3-24 hours after administration, mainly for 500 undefined Ampligen; At doses evaluated, intranasal Ampligen administration did not drive a significant change in nasal immune cell abundance. AIM Chief Executive Officer Thomas Equels stated: "The results from this Phase 1 study evaluating intranasal Ampligen in healthy subjects support the promising potential in the ability of Ampligen to inhibit respiratory viruses at the point of entry. The repeated intranasal dosing regimen was shown to be well tolerated in all tested dose levels. These Phase 1 data, in combination with the prior promising results of in vitro modelling which demonstrated that Ampligen could decrease SARS-CoV-2 infectious viral yields by 90% at clinically achievable intranasal Ampligen dosage levels, continue to be encouraging as we advance the development of Ampligen as a potential intranasal prophylactic approach to prevent infection and spread of COVID-19." In a randomized, double-blind, placebo-controlled, dose-escalation study, Ampligen or placebo was administered in both nostrils every other day, for a total of 7 consecutive doses. Safety and tolerability were monitored for 28 days after first dosing. Type I interferon, NFB-mediated cytokines and chemokines were measured. Mucosal immune cells were characterized using spectral flow cytometry.

08:08 EST Corcept Therapeutics says miricorilant did not reverse AIWG in trials - Corcept Therapeutics announced an update to its programs evaluating the proprietary selective cortisol modulator miricorilant in patients with antipsychotic-induced weight gain and non-alcoholic steatohepatitis. "Miricorilant did not reverse AIWG in either our GRATITUDE or GRATITUDE II trials," said Bill Guyer, PharmD, Corcept's Chief Development Officer. "However, miricorilant was clearly active in the liver. We will present full results at a medical conference next year. Based on multiple, replicated pre-clinical results as well as on the results of our Phase 1 study in which miricorilant significantly reduced weight gain experienced by healthy volunteers administered olanzapine, we plan to further study miricorilant's potential to prevent AIWG. Miricorilant continues to demonstrate great promise as a treatment for NASH," added Dr. Guyer. "Our on-going dose-finding study has identified a range of doses, all substantially lower than our originally tested doses, that appear to cause large reductions in liver fat, without causing excessive liver irritation. We plan to start a Phase 2 trial next year."

08:06 EST Enphase Energy expands IQ8 microinverter deployments in Northern California - Enphase Energy announced that installers of Enphase products in Northern California have seen growing deployments of Enphase Energy Systems powered by IQ8 Microinverters. Enphase's revolutionary IQ8-based systems can provide Sunlight Backup functionality during an outage, even without a battery. In addition, with the Sunlight Jump Start feature, IQ8 Microinverters can restart a home energy system using sunlight only after prolonged grid outages that may result in a fully depleted battery. "We work with exceptional solar installers across Northern California that pride themselves on offering world-class products and support to homeowners," said Dave Ranhoff, chief commercial officer at Enphase Energy. "IQ8 Microinverters give homeowners more flexibility and independence from the grid so they can generate, use, store, and monitor their own renewable energy."

08:05 EST Eiger BioPharma's lonafarnib meets endpoints in Phase 3 HDV trial - Eiger BioPharmaceuticals announced topline primary Week 48 data from its Phase 3 D-LIVR study evaluating lonafarnib, a first-in-class prenylation inhibitor, in two regimens in patients with chronic Hepatitis Delta Virus, or HDV: lonafarnib boosted with ritonavir alone and in combination with peginterferon alfa - combination -. The composite primary endpoint was a greater than or equal to2 log decline in HDV RNA and normalization of alanine aminotransferase at the end of 48 weeks of treatment compared to placebo. Topline Week 48 results showed that both treatment arms achieved statistical significance over placebo in the composite primary endpoint as well as the component virologic and biochemical responses. Study participants receiving the all-oral therapy and combination therapy showed a composite response of 10.1% and 19.2% respectively vs. those receiving placebo - 1.9% -. Study participants receiving the all-oral therapy and combination therapy showed statistically significant improved rates of ALT normalization of 24.7% and 34.4% respectively, compared to those receiving placebo - 7.7% -. The key secondary histological endpoint was defined as greater than or equal to 2-point improvement in histological activity index and no worsening of Ishak fibrosis scoring. This was demonstrated in 35 of 66 patients with statistical significance in the combination arm versus 8 of 30 patients - 27% - receiving placebo. Response was demonstrated in 35 of 107 patients in the all-oral arm versus placebo. Response in the peginterferon alfa comparator arm was 10 of 26 patients. Remaining secondary endpoints are being collected and are expected to be reported mid-2023. The majority of treatment emergent adverse events were mild or moderate in severity. The most frequent TEAEs associated with lonafarnib treatment were gastrointestinal. Eiger plans to engage with regulatory agencies, beginning with a pre-NDA meeting with FDA anticipated in Q1 2023, to discuss pathways for regulatory submissions.

08:04 EST Banzai to become publicly-traded via 7GC & Co. business combination - Banzai International and 7GC & Co. Holdings announced they have entered into a definitive business combination agreement that will result in Banzai becoming a publicly traded company. Upon closing of the proposed transaction, the combined company will be named Banzai International, Inc. and is expected to trade on the Nasdaq Capital Market. Banzai is an end-to-end video engagement solution that provides a fast, intuitive and powerful platform of marketing tools that create more intent-driven videos, webinars, virtual events, and other digital marketing campaigns. Through Banzai's full-stack technology, marketers can leverage live and automated, no-download hosting for video marketing content such as webinars and virtual events and multi-channel targeted audience acquisition to bolster engagement and ROI. Banzai enables over 7,0001 marketing teams to create winning webinars and virtual events that increase marketing efficiency and drive additional revenue. Banzai and Hyros Inc have also entered into a merger agreement, where immediately prior to the closing of the proposed transaction between Banzai and VII, Banzai will acquire Hyros for approximately $110 million in a primarily stock transaction. Hyros' strength is growing revenue attribution for digital marketers, helping enterprise and SMB customers get accurate sales and marketing data that they can leverage into making better ROI decisions. The acquisition is expected to enhance Banzai's role as a full-stack marketing technology platform, expand its total addressable market and accelerate its long-term revenue growth and operational efficiency. The integration of the Hyros multi-channel attribution and AI optimization capabilities for digital businesses is expected to significantly enhance the Banzai platform. The combined company is expected to have an estimated post-transaction enterprise value of $380 million, consisting of an estimated equity value of $580 million, $207 million in cash, and $7 million in debt, assuming no redemptions of VII public shares by VII public stockholders. Cash proceeds raised are expected to consist of VII's approximately $230 million of cash in trust. Banzai is a party to a Share Purchase Agreement with GEM Global Yield LLC SCS and GEM Yield Bahamas Limited, pursuant to which GEM has agreed to purchase from the Company up to a number of authorized, validly issued, fully paid and non-assessable shares of Banzai common stock having an aggregate value of $100,000,000, which should allow the combined company post-closing to opportunistically take in additional capital in the event of high redemptions or if additional capital is needed. The net proceeds raised from the proposed transaction will be used to support Banzai strategic growth along its expansion vectors of inorganic growth opportunities, geographic expansion, customer type enlargement, sales channels additions and vertical extension. Current Banzai management, employees and existing shareholders will roll 100% of their existing equity holdings into equity of the combined company. Existing Banzai security holders will receive approximately 50% of the pro forma equity of the combined company as part of the transaction, assuming no redemptions of VII's public shares. The business combination has been approved by the boards of directors of both Banzai and VII and is expected to close in the first half of 2023, subject to regulatory and stockholder approvals and other customary closing conditions.

08:03 EST Eyenovia promotes Kern to CHief Operating Officer, Corporate Vice President - Eyenovia announced that Bren Kern, who currently serves as Eyenovia's Senior Vice President of Manufacturing and Operations, has been promoted to Chief Operating Officer and Corporate Vice President, effective January 1st. Kern has spent his career helping companies transition from research and development entities into scaled commercial manufacturing organizations. Eyenovia also announced today that independent director Julia Haller, MD is stepping down from the company's Board of Directors. Upon her departure, Eyenovia's Board will be reduced to seven seats from eight.

08:00 EST HCW Biologics enters CRADA with National Cancer Institute - HCW Biologics announced that under a Cooperative Research and Development Agreement, the National Cancer Institute and HCW Biologics Inc. will collaborate to perform a Phase 1b/2 clinical study to evaluate the safety and tolerability of HCW Biologics' proprietary agent, HCW9218, in patients with advanced/metastatic pancreatic cancer. The CRADA is entitled, "A Phase 1b/2 Study of HCW9218, a Bifunctional TGF- beta Antagonist/IL-15 Protein Complex, for Advanced Pancreatic Cancer." The Principal Investigator at NCI is Christine Alewine, M.D., Ph.D. Dr. Alewine is a Lasker Clinical Research Scholar at the National Institutes of Health in the Laboratory of Molecular Biology.

07:59 EST Jounce Therapeutics presents INNATE Phase 1, SELECT trial data - Jounce Therapeutics reported new clinical data from the INNATE trial with JTX-8064 and pimi and the SELECT trial with vopra and pimi in two poster presentations at the ESMO-IO 2022 Annual Congress being held in Geneva, Switzerland. JTX-8064 is a highly selective and potent inhibitor of myeloid-specific Leukocyte Immunoglobulin Like Receptor B2 with the potential to reverse PD-(L)1 inhibitor resistance. JTX-8064 is being studied in the INNATE trial, a Phase 1/2 dose escalation/expansion trial of two investigational agents, JTX-8064 monotherapy and combination with pimi, Jounce's investigational PD-1 inhibitor. Vopra is an inducible T cell costimulator agonist monoclonal antibody that stimulates CD4 T cells and may amplify anti-tumor activity. The SELECT trial is a randomized Phase 2 trial of vopra combined with pimi versus pimi monotherapy in TISvopra biomarker selected, immunotherapy naive, 2nd line non-small cell lung cancer patients. In the poster titled "Phase 1 Study of JTX-8064, a LILRB2 inhibitor, as monotherapy and combination with pimivalimab, a PD-1 inhibitor, in patients with advanced solid tumors" Phase 1 data defining the recommended Phase 2 dose were presented. Patients with advanced solid tumors who progressed after all available therapy were treated at seven dose levels of JTX-8064 mono and two dose levels of JTX-8064 plus pimi 500 mg q3w using a Bayesian design. The study's primary objectives are safety and determination of the RP2D. Secondary objectives are pharmacokinetics, receptor occupancy, and immunogenicity, and exploratory objectives include evaluation of anti-tumor activity including objective response rate by RECIST 1.1 criteria. Thirty-one patients were treated in dose escalation, 22 JTX-8064 mono, and nine JTX-8064 plus pimi. There were no dose limiting toxicities and maximum tolerated dose was not reached. Eleven monotherapy patients and six combination patients had treatment-related adverse events, most of which were Grade 1 or 2, and there was only one serious TRAE, a tumor flare in the 1200 mg mono cohort. PK was linear. Full RO through 21 days was achieved at greater than or equal to 300 mg resulting in selection of an RP2D of 700 mg q3w for JTX-8064 +/- pimi. Phase 1 efficacy data in the mono cohort: zero partial response, seven stable disease including two durable SD. Phase 1 efficacy data in the combo cohort: one confirmed PR at 700 mg in a PD-1i resistant cholangiocarcinoma patient and resolution of both bone pain and cachexia, three SD with one durable SD of 6 months. Enrollment into multiple expansion cohorts is ongoing. A poster titled "SELECT: A phase II randomized trial evaluating 2 doses of vopratelimab + pimivalimab vs P in TISvopra selected patients" of the vopra plus pimi SELECT trial included an update to data previously announced on clinical endpoints, including additional durability data for patients who remain on study. SELECT is a randomized Phase 2 trial evaluating vopra, Jounce's ICOS agonist, in combination with pimi versus pimi alone in 69 immunotherapy naive, second line, non-small cell lung cancer patients. Two hypotheses were tested in the study. First, two different doses were examined, both intended to result in different levels of pulsatile target engagement, which may optimize the dose of an agonist by reducing T cell exhaustion. Second, all patients in the study were selected by TISvopra, an 18 gene RNA tumor inflammation signature, previously associated with improved clinical outcomes in patients treated with vopra +/- nivolumab. Sixty nine TISvopra positive patients with metastatic NSCLC after one prior platinum-containing regimen were randomized 2:1:1 to pimi monotherapy 1000 mg, vopra 0.1 mg/kg plus pimi or vopra 0.03 mg/kg q6w plus pimi. Both doses of vopra demonstrated distinct patterns of pulsatile target engagement while vopra 0.03 mg/kg achieved a shorter duration of target engagement and a meaningful rest period from receptor saturation and signaling was observed. The low dose vopra combination trended favorably for the primary endpoint, ORR, and progression free survival. ORR was 40% for low dose vopra combination cohort, 27.8% for pimi alone, and 16.7% for high dose vopra combination cohort. Six month landmark PFS was 80% for low dose vopra combination, 36% for pimi monotherapy, and 31% for high dose vopra combination. Benchmarks for approved PD-1 inhibitors in second line IO naive NSCLC are ORR 18-20% and 6 month landmark PFS 30-38%. PD-L1 was evenly distributed across TISvopra patients and not associated with efficacy, suggesting TISvopra may select for patients who respond independent of PD-L1. Study treatment was well tolerated with 7.2% of patients reporting Grade greater than or equal to3 TRAEs. Most common TRAEs were Grade 1/2 hyperthyroidism and hypothyroidism. Preclinical data demonstrating that a shorter period of target engagement with vopra in vitro stimulates T cells without the exhaustion seen with longer treatment was also summarized in the poster. This data provides a scientific rationale that clinical outcomes obtained with lower doses of vopra may be improved relative to doses that result in continuous target engagement, as the SELECT clinical data suggests. Jounce plans to pursue a partnership to enable further development of vopra 0.03 mg/kg in combination with a PD-1 inhibitor.

07:42 EST Rekor Systems finalizes sale of ATSE business to Altumint - Rekor Systems announced the closing of the sale of the Company's Automated Traffic Safety Enforcement business to Altumint. The sale is the result of the Company's previously announced strategic shift towards prioritizing its core data services businesses.

07:41 EST Bannix announces intent to extend deadline to complete business combination - Bannix Acquisition announced that its sponsor, Bannix Management has provided the Company notice of its intent to extend the deadline by which the Company must complete a business combination by three months, from December 14, 2022 to March 14, 2023. In order to fund the $690,000 deposit required to allow for such extension, the Company will obtain a loan from Instant Fame evidenced by a non-interest-bearing promissory note that is payable upon the consummation of a business combination by the Company. If the Company fails to consummate a business combination, the outstanding debt under the promissory note will be forgiven, except to the extent of any funds held outside of the Company's trust account after paying all other fees and expenses of the Company.

07:40 EST Cytokinetics presents data at virtual International Symposium on ALS/MND - Cytokinetics announced that data were presented at the Virtual 33rd International Symposium on ALS/MND related to survival predictions from FORTITUDE-ALS, the Phase 2 clinical trial of reldesemtiv in ALS. Precited Survival Risk Score for Participants in FORTITUDE-ALS Strongly Correlated with Decline in ALSFRS-R: In a previously presented post-hoc analysis of disease progression in FORTITUDE-ALS, patients were grouped into tertiles according to their pre-study rate of decline in the ALS Functional Rating Scale Revised total score. In this analysis, the ENCALS survival model was used to calculate a predicted survival risk score for all participants in FORTITUDE-ALS. Based on their risk score, participants were assigned to one of five risk groups based on predicted survival. When participants who met the 24/44 criteria and those who did not were categorized according to their ENCALS risk score, those who met the criteria were primarily in the G1, G2 or G3 groups associated with fast or intermediate progression and shorter predicted survival, whereas those who did not meet the criteria were primarily in the G4 and G5 risk groups associated with slow progression and longer survival. These findings suggest that ENCALS risk scores are strongly correlated with the rate of decline in the ALSFRS-R. In the ongoing Phase 3 trial of reldesemtiv, COURAGE-ALS (Clinical Outcomes Using Reldesemtiv on ALSFRS-R in a Global Evaluation in ALS, in order to enhance the ability to detect a treatment effect, participants must meet the 24/44 criteria to enroll in the trial. Findings from the current analysis of FORTITUDE-ALS suggest that implementing the 24/44 inclusion criteria will enrich for the enrollment of participants with more rapidly progressing disease, while minimizing, but not excluding, participants with more slowly progressing disease. COURAGE-ALS & COURAGE-ALS OLE: Trial Design: COURAGE-ALS, a Phase 3, multi-center, double-blind, randomized, placebo-controlled trial of reldesemtiv is expected to enroll approximately 555 patients with ALS. The primary efficacy endpoint is change from baseline to 24 weeks in ALSFRS-R. Secondary endpoints include combined assessment of ALSFRS-R total score, time to onset of respiratory insufficiency and survival time up to week 24 using a joint rank test; change from baseline to 24 weeks for vital capacity; ALSAQ-40; and bilateral handgrip strength. Two unblinded interim analyses by the Data Monitoring Committee are planned. The first interim analysis assessing for futility occurred 12 weeks after approximately one-third or more of the planned sample size was randomized, and the Data Monitoring Committee recommended that the trial continue. An open-label extension trial, COURAGE-ALS OLE, is open to people who have completed participation in COURAGE-ALS. The primary endpoint is the incidence of adverse events. Secondary endpoints include the time to the first occurrence of respiratory insufficiency or death, time to the first hospitalization, combined assessment of change in ALSFRS-R total score, time to onset of respiratory insufficiency, and survival time, changes in ALSFRS-R total score, and the slope of changes in ALSFRS-R total score.

07:38 EST Rekor Systems finalizes sale of ATSE business to Altumint - Rekor Systems announced the closing of the sale of the company's Automated Traffic Safety Enforcement, or ATSE, business to Altumint, a provider of automated traffic law enforcement, traffic monitoring, and forensic investigations. The sale is the result of the Company's previously announced strategic shift towards prioritizing its core data services businesses.

07:37 EST Sensei Biotherapeutics sees cash runway into 2H25

07:37 EST Williams executes agreements with Coterra Energy, Dominion for next gen gas - Williams (WMB) announced the execution of agreements with Coterra Energy (CTRA) and Dominion Energy Virginia (D) establishing the industry's first next generation natural gas certification process across all segments of the value chain from production through gathering and transmission with deliveries through 2023. Williams is leveraging block-chain secured technology via Context Labs' Decarbonization as a Service(TM) (DaaS(TM)) platform to track and measure end-to-end emissions through the aggregation and reconciliation of multiple sources of data to provide a path-specific methane intensity certification that meets or exceeds industry leading measurement protocols. KPMG LLP will perform third-party verification of the methane intensity certification and low-emission attributes of next gen natural gas.

07:36 EST SiriusPoint announces new international leadership team - SiriusPoint has appointed Rob Gibbs as President of its international business and to CEO of SiriusPoint International Insurance Corporation. The CEO appointment is conditional and effective upon regulatory approval. Gibbs joins the Company on 12 December, 2022. He will be responsible for the management and oversight of runoff activities and oversee the ongoing transformation of the SiriusPoint International platform, working closely for a handover period with outgoing CEO Monica Cramer Manhem. Cramer Manhem announced her retirement last month after 38 years with the company and its predecessor businesses. Gibbs, who brings 24 years of re/insurance industry experience to SiriusPoint, was most recently Commercial Managing Director of Royal Sun Alliance in the UK. SiriusPoint also announced that Anders Hjelm has been promoted to Deputy Chief Executive Officer of SiriusPoint International Insurance Corporation, effective December 12, 2022, subject to regulatory approval. Additionally, Jennifer Bowie has been appointed interim Chief Underwriting Officer of SiriusPoint International, also effective December 12, 2022.

07:35 EST Covetrus Sysco appoints Ajoy Karna as CFO - Covetrus (CVET) announced the appointment of Ajoy Karna as executive vice president and chief financial officer. Karna succeeds Matthew Foulston, who announced previously his retirement from the company. Karna joins Covetrus from Sysco (SYY), where during his 10 years with the company, he held a number of senior finance and strategic leadership roles.

07:34 EST Actinium, Columbia University to study Actimab-A in AML patients - Actinium Pharmaceuticals has entered into a research collaboration with Columbia University to study Actimab-A, its clinical-stage CD33 targeting radiotherapeutic, with engineered hematopoietic stem cells - eHSCs - modified by CRISPR/Cas9 gene editing technology to knock out CD33 expression. Under this collaboration, Actimab-A will be administered following transplantation of the eHSCs with the goal of eliminating any CD33 positive residual AML cells. This would allow a patient to receive CD33 targeting therapy post-transplant to eradicate any residual CD33 positive leukemia cells and prevent relapse while sparing newly formed blood cells that do not express CD33. Actimab-A has been studied in over 150 AML patients in six clinical trials. Recently, Actimab-A demonstrated high rates MRD negativity resulting in a 53% 1-year overall survival and 32% 2-year overall survival in a patient group that has an expected overall survival of less than 3 months.

07:32 EST NexGel launches Turfguard to treat burns, protect sport-related wounds - NEXGEL announced that it has launched a new product dubbed Turfguard, a unique hydrogel dressing for soothing turf burn and protecting athletic wounds. Turfguard's sterile silver patches, cleared by the U.S. Food and Drug Administration, kill 99 percent of staph, MRSA and strep. "For athletes, turf burns and skin abrasions are often a common, unfortunate part of the game," said Adam Levy, Chief Executive Officer, NEXGEL. "Additionally, turf fields and other shared equipment frequently house harmful bacteria, such as MRSA, that can lead to serious health complications. NEXGEL's proprietary Turfguard patches can be used on superficial burns, abrasions or lacerations and has been shown to kill staph, MRSA and strep. What's more, these dressings have a high-water content making them delicate on the skin and helping the area to heal quickly. This product is a must-have for training rooms across football, lacrosse, wrestling, gymnastics and many other applicable sports."

07:28 EST Chart Industries announces proposed offerings of stock, depositary shares - Chart Industries announced that, subject to market and other conditions, it has commenced concurrent offerings of $600 million of common stock, par value $0.01 per share, and $300 million of depositary shares, each representing a 1/20th interest in a share of Series B Mandatory Convertible Preferred Stock, par value $0.01 per share, each in a separate underwritten registered public offering. In addition, Chart expects to grant the underwriters in each respective offering a 30-day option to purchase up to an additional $90 million of Common Stock and up to an additional $45 million of Depositary Shares. Chart intends to use the proceeds from the Offerings to fund in part the previously announced acquisition of Howden from affiliates of KPS Capital Partners, LP by reducing the amount of Series A Cumulative Participating Convertible Preferred Stock to be issued to Granite Holdings I B.V., a Dutch private limited liability company, under the equity purchase agreement in connection with the Acquisition. Holders of the Depositary Shares will be entitled to a proportional fractional interest in the rights and preferences of the Preferred Stock, including conversion, dividend, liquidation and voting rights, subject to the provisions of a deposit agreement. Unless earlier converted, each share of the Preferred Stock will automatically convert on or around December 15, 2025 into a number of shares of Common Stock based on the applicable conversion rate, and each Depositary Share will automatically convert into a number of shares of Common Stock equal to a proportionate fractional interest in such shares of Common Stock. The conversion rates, dividend rate and other terms of the Preferred Stock will be determined at the time of pricing of the offering of the Depositary Shares. Currently, there is no public market for the Depositary Shares or the Preferred Stock. Chart intends to apply to list the Depositary Shares on the New York Stock Exchange under the symbol "GTLS.PRB."

07:17 EST Can-Fite BioPharma announces progress in Vetbiolix Piclidenoson studies - Can-Fite BioPharma announced progress achieved in the development of Piclidenoson for' the treatment of osteoarthritis in dogs by the company's veterinary commercialization partner Vetbiolix, which is covering all costs associated with veterinary clinical development. Vetbiolix completed dose-ranging pharmacokinetic, or PK, studies in dogs and determined the optimal efficacy and safety dosage for its upcoming European multicentric clinical study. Piclidenoson was well tolerated, with the PK data proportional to dose. Pre-clinical studies were also conducted showing Piclidenoson has a very favorable safety profile. Based on these data, Vetbiolix has designed a European Multicentric Clinical study protocol for dogs with osteoarthritis which has been approved by an ethical committee. In June 2021, Can-Fite entered an agreement with Vetbiolix, a France-based veterinary biotech company, for the treatment of osteoarthritis in companion animals including dogs and cats. Vetbiolix has the exclusive right to Piclidenoson in the veterinary osteoarthritis market for two years, during which time Vetbiolix is conducting studies and covering all associated costs. If the efficacy study yields positive data and Vetbiolix exercises its option to obtain the license from Can-Fite, then Vetbiolix will be obligated to pay Can-Fite upfront and milestone payments, in addition to royalties on sales upon regulatory approval.

07:16 EST Cabaletta Bio announces $35M offering - Cabaletta Bio announced that it has agreed to sell, by way of an underwritten public offering, pre-funded warrants, in lieu of common stock, to purchase 6,213,776 shares of common stock at a price of $5.51999 per pre-funded warrant and 126,815 shares of its common stock at a price of $5.52 per share, for expected aggregate gross proceeds of approximately $35M, before deducting underwriting discounts and commissions and other estimated offering expenses. The purchase price per share of each pre-funded warrant represents the per share public offering price for the common stock, minus the $0.00001 per share exercise price of such pre-funded warrant. The offering is expected to close on December 12, 2022, subject to customary closing conditions. All of the securities are being offered by Cabaletta. The oversubscribed offering involved participation from new and existing investors, including Venrock Healthcare Capital Partners, Adage Capital Partners LP, Cormorant Asset Management and an undisclosed life sciences-focused investment fund, among others. Cowen and Company, LLC and Evercore Group L.L.C. are acting as joint book-running managers for the offering. Cabaletta intends to use the net proceeds from the offering, together with existing cash and cash equivalents, to fund the completion of preclinical development and the Investigational New Drug application submission for CABA-201, the initial clinical development of CABA-201 in multiple indications and the ongoing clinical studies for its DSG3-CAART and MuSK-CAART product candidates, as well as for working capital and general corporate purposes.

07:13 EST OTC Markets Group welcomes Patriot Battery Metals to OTCQX - OTC Markets Group announced Patriot Battery Metals has qualified to trade on the OTCQX Best Market. Patriot Battery Metals Inc upgraded to OTCQX from the OTCQB Venture Market.

07:12 EST Roche Alzheimer's disease Cerebrospinal Fluid assays receive FDA clearance - Roche announced that its Elecsys beta-Amyloid CSF II and Elecsys Phospho-Tau CSF assays have received U.S. Food and Drug Administration 510(k) clearance. "The Elecsys AD CSF Abeta42 and pTau181 assays, used as a pTau181/Abeta42 ratio, measure two biomarkers that are hallmarks of Alzheimer's pathology, beta-amyloid and tau proteins, in adults ages 55 and older being evaluated for the disease... The Elecsys AD CSF assays achieve 90% concordance with the Amyloid PET scan imaging and have the potential to provide a more affordable and accessible routine option to confirm the presence of amyloid in the brain. They also offer detection of multiple biomarkers from one draw, with no radiation and potential to detect Alzheimer's pathology in early stages of disease," the company said.

07:10 EST Atlas Technical selected to provide environmental services in Washington state - Atlas Technical Consultants announced that it was awarded a $5M contract to provide Environmental and Quality Assurance Services to the Washington State Department of Transportation, WSDOT. Atlas' technical staff will support WSDOT in its efforts to remove fish barriers and improve fish migration patterns in streams and rivers across the state. "Atlas has a strong history of providing environmental and quality assurance services in Washington state and throughout the Pacific Northwest," said L. Joe Boyer, Atlas' Chief Executive Officer. "We are committed to helping our clients meet their environmental goals and are looking forward to providing a comprehensive set of technical services on this important project."

07:09 EST Microbot Medical's LIBERTY Robotic System receives third patent in Israel - Microbot Medical continues to strengthen its intellectual property portfolio, while advancing and securing its global commercialization strategy. It has been granted a third patent in Israel for the LIBERTY Robotic System, covering the core capabilities of the system, such as a compact robotic device for driving movement of two or more surgical devices and having motors and actuation assemblies encased within the same volume.

07:07 EST In8bio announces FDA clearance to initiate Phase 2 trial of INB-400 - IN8bio announced that it has received clearance of its Investigational New Drug, IND, application from the U.S. Food and Drug Administration, FDA, to initiate a Phase 2 clinical trial of a genetically modified autologous gamma-delta T cell therapy, INB-400, targeting newly diagnosed glioblastoma, GBM. The study will assess the safety, efficacy and tolerability of genetically modified DeltEx drug-resistant immunotherapy, DRI, cells at leading medical centers across the United States. "Obtaining clearance to begin the INB-400 Phase 2 clinical trial is an important milestone for IN8bio as it is our first company-sponsored IND. This milestone demonstrates the clinical, regulatory and CMC capabilities of the IN8bio team in continuing to advance novel gamma-delta T cell therapies to cancer patients," said William Ho, Chief Executive Officer and co-founder of IN8bio. "The clinical program is designed to eventually assess DeltEx DRI with both autologous and allogeneic approaches in both the front-line and relapsed setting. We believe the insights we unlock in GBM will be essential as we apply our DeltEx platform across multiple solid tumor cancers."

07:07 EST D-Wave Quantum announces agreement with uptownBasel Infinity - D-Wave Quantum announced an agreement that brings D-Wave's quantum annealing technology solutions to the new uptownBasel Infinity Center of Competence for Quantum & AI. Designed to accelerate quantum computing understanding and adoption, the center provides organizations with quantum skills enablement and access to a variety of quantum computing systems and renowned industry expertise to help them harness the power of the technology to solve computationally complex business and societal problems. D-Wave will serve as the quantum optimization technology provider for uptownBasel Infinity, giving the center's tenants and customers access to its AdvantageTM annealing quantum computer via the Leap real-time quantum cloud service. Advantage, D-Wave's fifth generation commercially available quantum computer with more than 5,000 qubits and 15-way qubit connectivity, excels at optimization problems ubiquitous in real-world commercial applications, such as manufacturing processes and reducing waste. In addition, the center's customers can engage with D-Wave's team of professional services experts to facilitate the analysis, formulation and ultimately creation of production-ready quantum computing applications.

07:06 EST Intensity Therapeutics' INT230-6 shows efficacy in breast tumor reduction - Intensity Therapeutics presented new data from the INVINCIBLE study at the San Antonio Breast Cancer Symposium December 6-10. The study is a phase 2, randomized study that enrolled 91 women with newly diagnosed, operable early-stage intermediate or high-grade T1-T2 invasive breast cancers 2 to 5 weeks prior to surgery. INT230-6 demonstrated the ability to cause up to 100% necrosis of presurgical breast cancer tumors in the window period from diagnosis to surgery. Pathway enrichment analysis demonstrated changes in T cell activation, lymphocyte activation and inflammatory response. Analysis is ongoing for part 2 of the clinical trial for changes in Ki67 and other parameters. Adverse events were mostly grade 1 with expected pain at the breast injection site; there were very few systemic adverse effects.

07:05 EST Vertex Pharmaceuticals, Entrada Therapeutics enter EEV therapeutics pact - Vertex Pharmaceuticals (VRTX) and Entrada Therapeutics (TRDA) announced a collaboration focused on discovering and developing intracellular Endosomal Escape Vehicle, or EEV, therapeutics for myotonic dystrophy type 1, or DM1. The collaboration includes Entrada's program for DM1, ENTR-701, which is in late-stage preclinical development. Under the terms of the agreement, Entrada will receive an upfront payment of $224M, as well as an equity investment of $26M. Entrada is eligible to receive up to $485M for the successful achievement of certain research, development, regulatory and commercial milestones, and tiered royalties on future net sales for any products that may result from this collaboration agreement. The agreement includes a four-year global research collaboration whereby Entrada will continue to advance and receive payments for certain research activities related to ENTR-701, as well as additional DM1-related research activities. Vertex will be responsible for global development, manufacturing and commercialization of ENTR-701 and any additional programs stemming from Entrada's DM1 research efforts. The collaboration is subject to review under the Hart-Scott-Rodino Antitrust Improvements Act.

07:04 EST Akero Therapeutics announces efruxifermin granted BTD from U.S. FDA - Akero Therapeutics announced that efruxifermin, EFX, has received a Breakthrough Therapy Designation, BTD, from the US Food and Drug Administration, FDA, for the treatment of nonalcoholic steatohepatitis, NASH. "We are proud to have the FDA recognize the potential therapeutic benefit of EFX through this Breakthrough Therapy Designation," said Andrew Cheng, M.D., Ph.D., president and chief executive officer of Akero. "With the global prevalence of NASH continuing to rise, we are committed more than ever to developing therapeutics that can treat NASH holistically and reverse fibrosis rapidly. This designation is an important milestone for Akero and the NASH community as we continue to evaluate EFX as a potential foundational monotherapy." In HARMONY, Akero observed that both 50mg and 28mg doses of EFX produced at least a one stage improvement in liver fibrosis with no worsening of NASH by week 24 compared with 20% for placebo. In addition to meeting this primary endpoint, the study also met two key secondary endpoints with 76% and 47% of patients treated with 50mg and 28mg, respectively, achieving NASH resolution without worsening of fibrosis, compared with 15% for placebo. An additional Phase 2b study, SYMMETRY, was initiated in July of 2021. Akero expects to report results from the ongoing SYMMETRY study in the second half of 2023. Results from a 12-week expansion cohort of the SYMMETRY study, evaluating treatment of EFX in combination with GLP-1 therapy in patients with F1-F3 fibrosis, are expected in the first half of 2023.

07:03 EST Better Therapeutics announces LivVita study met its primary endpoint - Better Therapeutics announced topline results of the first-ever study evaluating the feasibility of using a prescription digital therapeutic to reduce liver fat and improve liver disease biomarkers in Nonalcoholic Fatty Liver Disease, or NAFLD, and Nonalcoholic Steatohepatitis, or NASH. The study included a cohort of 22 patients with NAFLD and NASH and used Magnetic Resonance Imaging - Proton Density Fat Fraction, or MRI-PDFF, scans, a validated proxy for liver biopsies, to monitor changes in liver fat. Changes in a range of exploratory liver biomarkers were also assessed. Currently, there is no FDA approved treatment for these conditions, which affect approximately one in four Americans and cause approximately $100B in direct medical cost annually. And while some drug candidates are in various phases of research and development, they often present side effects that could limit their utility in patients, if approved. The LivVita Study met its primary endpoint, showing a statistically significant positive signal with an average relative reduction in MRI-PDFF of 16% in the intent-to-treat population. Additional highlights include: A statistically significant mean reduction in Alanine transaminase (ALT) of -17 IU/L. A statistically significant mean change in FAST Score of 20%. No severe adverse events or device related adverse events. High engagement and patient satisfaction with treatment, with Net Promoter Score of +75 and 94% of subjects still using the app after 90 days.

07:03 EST Air Products, AES Corp. to invest $4B in new Texas green hydrogen facility - Air Products (APD) and AES Corporation (AES) plan to invest approximately $4B to build, own and operate a green hydrogen production facility in Wilbarger County, Texas. This mega-scale renewable power to hydrogen project includes approximately 1.4 GW of wind and solar power generation, along with electrolyzer capacity capable of producing over 200 metric tons per day of green hydrogen, making it the largest green hydrogen facility in the U.S. The facility, which is targeted to begin commercial operations in 2027, will serve growing demand for zero-carbon intensity fuels for the mobility market as well as other industrial markets. Air Products and AESi will jointly and equally own the renewable energy and electrolyzer assets, with Air Products serving as the exclusive off-taker and marketer of the green hydrogen under a 30-year contract. The project would create more than 1,300 construction and 115 permanent operations jobs, as well as about 200 transportation and distribution jobs. It is also expected to generate approximately $500M in tax benefits to the state over the course of the project's lifetime.

07:02 EST Novartis reports Phase 3 APPOINT-PNH study met primary endpoint - Novartis announced the Phase III APPOINT-PNH study of investigational oral monotherapy iptacopan in complement-inhibitor-naive, including anti-C5 therapies, adults with PNH met its primary endpoint. Topline results showed a significant proportion of patients treated with iptacopan achieved clinically meaningful hemoglobin-level increases of 2 g/dL or more from baseline without the need for blood transfusions at 24 weeks. In the study, the safety profile of iptacopan monotherapy was consistent with previously reported data. Detailed data will be presented at an upcoming medical meeting and included as part of global regulatory submissions in 2023. "We are very encouraged by the results of the complement-inhibitor-naive data from the Phase III APPOINT-PNH trial," said David Soergel, M.D., Global Head, Cardiovascular, Renal and Metabolism Development Unit, Novartis. "This second iptacopan readout for PNH underscores the robust potential for this therapy, enabling us to submit a broad regulatory package with the goal of iptacopan potentially becoming the first oral monotherapy for PNH."

06:55 EST Pharvaris' PHVS416 in HAE attacks meets primary and secondary endpoints - Pharvaris announced positive top-line data from the RAPIDe-1 Phase 2 clinical study, demonstrating statistically significant results of PHVS416 as an oral on-demand treatment for hereditary angioedema - or HAE - attacks. RAPIDe-1 is a Phase 2 dose-ranging study of PHVS416 softgel capsule for the acute treatment of angioedema attacks in patients with Type I or II HAE. Seventy-four patients were enrolled. The primary endpoint of the study is the change of a three-symptom composite visual analogue scale score from pre-treatment to four hours post-treatment. Topline data from 147 attacks collected by 62 patients show that dose levels of PHVS416 significantly reduces attack symptoms. All key secondary endpoints of the study were met, demonstrating that PHVS416 significantly: shortens the time to onset of symptom relief by a greater than or equal to30% reduction ; decreases time to a greater than or equal to 50% reduction in VAS-3 score; reduces time to almost complete or complete symptom relief by VAS-3; reduces mean symptom complex severity score from pre-treatment to four hours post-treatment. All other secondary endpoints were met. Participants on PHVS416 also used substantially less rescue medication compared to placebo. PHVS416 was generally well tolerated with no treatment-related serious adverse events and no adverse events leading to treatment discontinuation.

06:40 EST Immunocore presents ovarian cancer expansion data for IMC-C103C - Immunocore (IMCR) presented data for IMC-C103C, a bispecific T cell engager targeting MAGE-A4, in patients with ovarian cancer. The Phase 1 data, presented in a poster at the ESMO Immuno-Oncology 2022 Congress, include 33 heavily pre-treated patients with ovarian cancer, who received doses of greater than or equal to 90 mcg intravenously. All patients had platinum relapsed/refractory ovarian cancer. The safety profile was consistent with that reported previously and the mechanism of action, i.e., T cell activation. No related AE led to treatment discontinuation or death. At the time of data cut-off, 32 patients were evaluable for response, with one additional patient still on treatment and not having had first tumor assessment. Of the 17 evaluable MAGE-A4 positive patients, one had a durable Partial Response, with a duration of 12.7 months, one patient who had a Stable Disease converted to an unconfirmed PR after the poster data cutoff date and is still ongoing, and 5 had SD. Reductions in ctDNA were observed in over half of ctDNA evaluable patients - 12/22 -, including 7 with greater than or equal to 50% reductions, and even in those with low or zero MAGE-A4 expression. IMC-C103C is part of a co-development / co-promotion collaboration with Genentech, a member of the Roche Group (RHHBY) under which Immunocore shares program costs and profits equally. Both companies are evaluating next steps for the IMC-C103C program

06:37 EST Rapt Therapeutics reports Phase 1/2 results of FLX475 in advanced cancer - Rapt Therapeuticsreported a poster presentation at the ESMO IO Congress covering data from its ongoing Phase 1/2 clinical trial of FLX475 as monotherapy and in combination with pembrolizumab in patients with advanced cancer. The data showed a confirmed overall response rate of 31% - 4/13 patients - in Stage 1 of a Phase 2 expansion cohort of patients with checkpoint-naive NSCLC, including two responses which are ongoing for over one year. Of the 13 patients treated with 100 mg once-daily FLX475 and a standard regimen of pembrolizumab, eight patients had PD-L1 positive tumors. The confirmed response rate in the PD-L1 positive tumors was 38% - 3/8 - and in the PD-L1 negative tumors was 25% - 1/4 patients- . None of the four responders were PD-L1 high. In a separate Phase 2 expansion cohort of six patients with EBV+ NK/T cell lymphoma treated with FLX475 monotherapy, there were four responses, with two durable complete metabolic responses, one unconfirmed CMR and one unconfirmed partial metabolic response. The safety profile for FLX475 was favorable, consistent with that previously seen in healthy volunteers, and there was no evidence of increased severity or frequency of adverse events in combination therapy compared to either FLX475 or pembrolizumab monotherapy.

06:33 EST Exxon Mobil expects earnings, cash flow to double by 2027 vs. 2019

06:32 EST Exxon Mobil targets annual capital investments $20B-$25B through 2027 - ExxonMobil announced its corporate plan for the next five years, with a sizeable increase in investments aimed at emission reductions and accretive lower-emission initiatives, including its Low Carbon Solutions business. The corporate plan through 2027 maintains annual capital expenditures at $20-$25 billion, while growing lower-emissions investments to approximately $17 billion. This disciplined approach prioritizes high-return, low-cost-of-supply assets in the Upstream and Product Solutions businesses and supports efforts to reduce greenhouse gas emissions intensity from operated assets, as well as those emitted from other companies. The plan is expected to double earnings and cash flow potential by 2027 versus 2019 and supports the company's strategic priorities, which include leading the industry in safety, shareholder returns, earnings and cash flow growth; cost and capital efficiency; and reductions in greenhouse gas emissions intensity. "Our five-year plan is expected to drive leading business outcomes and is a continuation of the path that has delivered industry-leading results in 2022," said Darren Woods, chairman and chief executive officer. "We view our success as an 'and' equation, one in which we can produce the energy and products society needs - and - be a leader in reducing greenhouse gas emissions from our own operations and also those from other companies. The corporate plan we're laying out today reflects that view, and the results we've seen to date demonstrate that we're on the right course."

06:13 EST GE HealthCare Spin completion expected after market close on Jan. 3, 2023 - Public trading set for Jan. 4, 2023.

06:05 EST Sprouts Farmers Market names Alisa Gmelich as SVP, Chief Marketing Officer - Sprouts Farmers Market announced that Alisa Gmelich has joined the company as Senior Vice President, Chief Marketing Officer, effective December 5. Gmelich will report directly to Sprouts President and COO, Nick Konat, and will oversee Sprouts' marketing, advertising, and customer engagement. Gmelich brings more than 25 years of experience in brand development, marketing strategy, and customer loyalty to Sprouts. She most recently served as Chief Brand Officer at Auntie Anne's.

05:25 EST Addex Therapeutics extends term of collaboration agreement with Indivior - Addex Therapeutics announced that the research term of its collaboration agreement with Indivior for the discovery of novel oral gamma-aminobutyric acid subtype B, or GABAB, positive allosteric modulator, or PAM, drug candidates for the treatment of substance use disorder has been extended until June 30, 2023. As part of the amended agreement, Indivior will pay Addex an additional $1M to cover additional research activities during this extended period. Addex retains exclusive rights to develop its own independent GABAB PAM program and is advancing compounds in Charcot-Marie-Tooth type 1A neuropathy, chronic cough and pain.

05:15 EST Compass Pathways presents new COMP360 psilocybin therapy data - Compass Pathways announced that new data demonstrating the potential of COMP360 psilocybin therapy in depression have been presented at the annual meeting of the American College of Neuropsychopharmacology, or ACNP. The results were presented from an investigator-initiated, exploratory open-label study of investigational COMP360 psilocybin therapy in type II bipolar disorder and a mechanistic analysis of the phase 2b trial of COMP360 psilocybin therapy in treatment-resistant depression, or TRD. Early signals have been presented in a poster from an open-label pilot study, which investigated the safety and efficacy of a single 25mg dose of COMP360 psilocybin therapy in participants with type II bipolar disorder depression. The study, run by Scott Aaronson at Sheppard Pratt Baltimore, found that 86% of the participants met response and remission criteria for the Montgomery-Asberg Depression Rating Scale, or MADRS, at 12 weeks after COMP360 psilocybin therapy. There was no increase in the suicidality score based on the MADRS, no manic symptoms and no unexpected adverse events or difficulties with the dosing sessions reported throughout the study. New data from the recently published phase 2b trial of COMP360 psilocybin therapy, also presented at ACNP, further demonstrated its potential in treatment-resistant depression, and how it may work: Mechanism of action validated: experiencing emotional breakthrough and specific aspects of the subjective psychedelic experience predicted reductions in depression severity three weeks after receiving COMP360 psilocybin therapy. The relationship between positive psychedelic experience and treatment response was seen for all three doses studied. Effect of higher dose: whilst both the 10mg and 25mg dose of COMP360 psilocybin produced a subjective psychedelic experience, the 25mg dose was significantly better at reducing depressive symptoms compared to a 1mg dose, whereas the 10mg dose was not found to be significantly better than 1mg. Psychological support: the therapeutic alliance between the participant and therapist did not predict improvement in symptoms of depression, suggesting that COMP360 psilocybin may provide greater therapeutic effect via its pharmacological action. This hypothesis will be tested further in COMPASS' phase 3 program.

05:08 EST ArcelorMittal inaugurates EUR 200M Steelanol CCU project - ArcelorMittal inaugurated its flagship carbon capture and utilization, or CCU, project. The EUR 200M 'Steelanol' project is a first of its kind for the European steel industry. Utilizing carbon recycling technology developed by our project partner LanzaTech, the CCU plant uses biocatalysts to transform carbon-rich waste gases from the steelmaking process and from waste biomass into advanced ethanol, which can then be used as a building block to produce a variety of chemical products including transport fuels, paints, plastics, clothing and even cosmetic perfume, hence helping to support the decarbonization efforts of the chemical sector. The advanced ethanol will be jointly marketed by ArcelorMittal and LanzaTech under the Carbalyst brand name. Once production reaches full capacity the Steelanol plant will produce 80M liters of advanced ethanol, almost half of the total current advanced ethanol demand for fuel mixing in Belgium. It will reduce annual carbon emissions from the Ghent plant by 125,000 tons. Other partners involved in the Steelanol project are Primetals Technologies and E4tech. ArcelorMittal Ghent will soon inaugurate another first for the European steel industry, with its 'Torero' project set to come on stream in the first quarter of 2023. The EUR 35M Torero project is designed to process sustainable biomass for use as a raw material input into the blast furnace, hence lowering the volume of fossil coal used. This project will reduce annual carbon emissions in Ghent by 112,500 tons. ArcelorMittal Ghent intends to add a second reactor to its Torero project over the next two years, hence doubling the size of the project.